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Abstract
Cell migration is an essential and highly regulated process. Cells migrate to vascularize tissues, to form tissue,
and to respond to inflammation. Unfortunately, cell migration is also involved in numerous pathological
conditions such as in invasive tumors. Cells can migrate as individual cells or as collective groups of cells.
Particularly important in cell migration is the collective migration of cells as it is a hallmark of tissue
remodeling events during embryonic morphogenesis, wound repair, and cancer invasion. Perhaps,
angiogenesis is one of the most crucial collective migration processes as it is involved in multiple physiological
and pathological conditions such as formation of vasculature, wound healing, cancer progression and
metastasis. During angiogenesis, endothelial cells migrate collectively from existing vasculature in response to
a complex biochemical and mechanical cues to form multicellular structures that eventually develop into new
functional blood vessels. Angiogenesis is also a highly dynamic process where multiple cells rearrange and
coordinate within a sprout. Such dynamic rearrangement requires different cytoskeletal regulators such as
Rho GTPases proteins (RhoA, Rac, and Cdc42). Although the roles of Rho GTPase proteins have been well
characterized in 2D cell migration, little is known about their contributions in angiogenic morphogenesis.
Here, we engineered a 3D biomimetic microfluidic-based device, called AngioChip, where endothelial cells
are induced to migrate collectively from a pre-formed biomimetic cylindrical blood vessel into a 3D interstitial
collagen matrix. The sprouts in our AngioChip demonstrate in vivo-like morphogenetic features such as
formation of tip-stalk cells, lumen formation, filopodial-like protrusions in leading tip cells, and formation of
perfusable neovessels. Using this system, we examine the roles of Cdc42 to regulate many aspects of
angiogenic morphogenesis. We find that disturbing Cdc42 activity reduces formation of branches, migration
speed, and collective migration. Additionally, Cdc42 also negatively regulate filopodia formation. We also
develop the AngioChip into a pancreatic ductal adenocarcinoma (PDAC) on a chip to investigate the
interactions between pancreatic cancer cells and blood vessels. Vascular invasion, where PDAC cells invaded
towards the vasculature during tumor progression, is a hallmark of metastatic PDAC. Nevertheless, how
pancreatic tumor cells interact with the blood vessels remains largely unknown. Using our PDAC-on-a-chip,
we reveal a striking observation where PDAC cells invade and de-endothelialize the blood vessels. This de-
endothelialization process leads to vascular replacement in the blood vessels and is mediated by proliferation
of PDAC through Nodal/Activin-ALK7 signaling.
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ABSTRACT 
3D BIOMIMETIC MODEL FOR CELLULAR INVASION IN ANGIOGENESIS AND CANCER 
Duc–Huy T. Nguyen 
Christopher S. Chen 
Cell migration is an essential and highly regulated process. Cells migrate to vascularize tissues, to 
form tissue, and to respond to inflammation. Unfortunately, cell migration is also involved in 
numerous pathological conditions such as in invasive tumors. Cells can migrate as individual cells 
or as collective groups of cells. Particularly important in cell migration is the collective migration of 
cells as it is a hallmark of tissue remodeling events during embryonic morphogenesis, wound repair, 
and cancer invasion. Perhaps, angiogenesis is one of the most crucial collective migration 
processes as it is involved in multiple physiological and pathological conditions such as formation 
of vasculature, wound healing, cancer progression and metastasis. During angiogenesis, 
endothelial cells migrate collectively from existing vasculature in response to a complex 
biochemical and mechanical cues to form multicellular structures that eventually develop into new 
functional blood vessels. Angiogenesis is also a highly dynamic process where multiple cells 
rearrange and coordinate within a sprout. Such dynamic rearrangement requires different 
cytoskeletal regulators such as Rho GTPases proteins (RhoA, Rac, and Cdc42). Although the roles 
of Rho GTPase proteins have been well characterized in 2D cell migration, little is known about 
their contributions in angiogenic morphogenesis. Here, we engineered a 3D biomimetic 
microfluidic-based device, called AngioChip, where endothelial cells are induced to migrate 
collectively from a pre-formed biomimetic cylindrical blood vessel into a 3D interstitial collagen 
matrix. The sprouts in our AngioChip demonstrate in vivo-like morphogenetic features such as 
formation of tip-stalk cells, lumen formation, filopodial-like protrusions in leading tip cells, and 
formation of perfusable neovessels. Using this system, we examine the roles of Cdc42 to regulate 
many aspects of angiogenic morphogenesis. We find that disturbing Cdc42 activity reduces 
formation of branches, migration speed, and collective migration. Additionally, Cdc42 also 
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negatively regulate filopodia formation. We also develop the AngioChip into a pancreatic ductal 
adenocarcinoma (PDAC) on a chip to investigate the interactions between pancreatic cancer cells 
and blood vessels. Vascular invasion, where PDAC cells invaded towards the vasculature during 
tumor progression, is a hallmark of metastatic PDAC. Nevertheless, how pancreatic tumor cells 
interact with the blood vessels remains largely unknown. Using our PDAC-on-a-chip, we reveal a 
striking observation where PDAC cells invade and de-endothelialize the blood vessels. This de-
endothelialization process leads to vascular replacement in the blood vessels and is mediated by 
proliferation of PDAC through Nodal/Activin-ALK7 signaling. 
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CHAPTER 1: INTRODUCTION 
1.1 Cellular invasion in physiological and pathological contexts 
1.1.1 Cellular invasion in morphogenesis and cancer 
The ability for cells to migrate is essential for physiological functions such as immune-
surveillance, wound healing, and tissue morphogenesis during embryo development. Pathological 
processes such as in cancer invasion and metastasis also depend on the ability of malignant cells 
to transform, acquire motility and invasiveness to break away from their tissue of origin and seed 
distant organs to form secondary tumors (1). There are different modes of cell invasions: single cell 
migration, multicellular streaming, and collective migration (2). Although different modes of cellular 
invasion are important for many physiological and pathological processes, the purpose of this thesis 
will mostly focus on collective migration.  
Distinguished from collective migration is single-cell migration. Single-cell migration is 
characterized by invasion of individual cells without cell-cell interactions during migration and a low 
correlation in the migration pattern between a cell and its neighbors. Single-cell migration is further 
classified into two subtypes comprised of amoeboid and mesenchymal migration. In amoeboid 
migration, cells obtain a round cell-body and there are several variants depending on the protrusive 
activity of migrating cells. Examples for different variants of amoeboid migrations are 1) cells that 
change morphology rapidly with short thin protrusions, without blebs and move with high velocities 
(0.4–5 µm/min); 2) cells with blebbing morphology and move slower in chaotic movements; and 3) 
cells with short protrusions associated with proteolytic activity with speed ~0.1 µm/min (2). In 
mesenchymal phenotype, cells have an elongated or spindle-shaped body and long protrusions. 
The front protrusions are dynamic and rapidly extend and retract while the rear of the cells can stay 
immobile, resulting in a relatively slow net migration at ~0.2 µm/min (2). 
In contrast to single cell migration, both multicellular streaming and collective cell migration 
have common features such as movement of a group of cells and the migrating path is straighter 
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as compared to single cell migration. However, these two invasive modes share distinct 
characteristics. In multicellular streaming, cells that migrate along the same path are loosely or 
non-adherent. The streaming cells typically have speeds of 1-2 µm/min (3). On the other hand, in 
collective migration, cells within the group are held together by cell-cell junctions. There is also a 
high correlation of directionality between neighboring cells. These cells move as a single strand of 
cells led by a single leader cell or as broad sheet of cells led by several leader cells (3-5). Collective 
migration is typically the slowest mode of cell migration (0.01–0.05 µm/min) in multiple cell types 
including cancer, but faster collective migration (0.2–1 µm/min) is also observed in development 
(6-8). 
In single cell migration, a classified cyclic 5-step process has been described (9). The first 
step of single cell migration requires initial polarization of the cell cytoskeleton to distinguish 
between the front and rear of the migrating cells. During this step, extensive protrusions, either 
ruffles or pseudopods, are formed. The subsequent step requires the engagement of adhesion 
receptors of the integrin families (alpha and beta integrins). Adhesion receptors are clustered and 
recruit additional scaffolding proteins to form nascent adhesion complexes and mature focal 
adhesions. These focal adhesions bind cells to the substrata or extracellular matrix proteins 
(ECMs). In step 3, surface proteins, such as proteases (MT1-MMP, uPA/uPAR), are recruited to 
proteolytically cleave the ECMs providing space for the cells to expand forward. In step 4, shortly 
after integrin-ligand binding, actin filaments engage with adaptor as well as cross-linking and 
contractile proteins, such as myosin II, which stabilize and contract the actin polymers. In step 5, 
under tension and contraction created by myosin II, actin filaments are shortened to provide 
contraction, which allows the front end of the cell body to glide forward and rear end to retract. 
These five steps provide an adaptive and dynamic framework in most of the cell types. However, 
they might undergo adaptive modifications depending on the inherent molecular repertoire or 
specific functions of various cell types (9). 
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In collective cell migration, steps 1-4 of the migration cycle of each individual cell are 
retained. However, the mode of rear retraction and forward gliding of the cell body is now placed 
under an important modification. If the moving cells in the group are to remain connected to the 
rest of the moving cells within the group, trailing edge retracting drags the following cells along the 
emerging migration track. Therefore, the trailing edge exerts forces to the ECMs and cell-cell 
junctions. It is very likely that rear retraction and release of adhesive bonds towards the substrata 
are involved, yet the maintenance of cell-cell junctions allows transferring of the net migration vector 
on the following cells. Tracking of single cells within a cohesive migration group of cells in different 
locations reveals intact inner architecture of cells within a group (10). One additional important 
feature of collective migration is that leading edge extension, and force generation as well as trailing 
edge retraction is a shared process by several cells. In other words, there are three distinct set of 
cells within a cohesive migration group of cells: a group of leading edge cells that generates force, 
a group of passively dragged cells, and a trailing group of cells that execute retraction. All these 
three groups provide an asymmetry to the moving group. 
During development, many morphogenetic processes involved collective migration such 
as morphogenetic movement of inner blastocysts (11), epithelial budding and developing ducts 
during branching morphogenesis (12), and migration of epithelial cells at the rim of the optic and 
the invaginating thyroid gland (13). More complex collective migration examples include collective 
movement during the converging extension of the vertebrate embryo in the Xenopus (14, 15) or 
the closure of dorsal surface in Drosophila embryo (16). Outside the context of development, 
collective migration is also seen in adults, such as in physiological wound healing. During wound 
healing, the horizontal migration of epithelial cell sheets across the wound tissue helps contract 
and close the wound (17). At the same time, endothelial cells sprout from existing blood vessels to 
form new blood vessels to support the repaired tissues (18). 
While collective migration plays many important roles during embryo development, it is 
also a putative mechanism for invasion and metastasis of cancer. Evidence of collective migration 
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in cancer is present in not fully dedifferentiated tumors, high and intermediate differentiated 
tumors of epithelial origins such as lobular breast cancer, epithelial prostate cancer, large-cell 
lung cancer (19, 20), melanoma (21), and rhabdomyosarcoma (22). Two morphological and 
functional variants of collective migration in tumors have been observed in vivo through histology. 
The first mode is a result of protruding sheets and strands of cells that maintain contact with the 
primary site. This mode is typically observed in oral squamous-cell carcinoma, mammary 
carcinoma (19), colon carcinoma (23), melanoma, and basal cell carcinoma. A second mode is 
characterized as groups of cells, seen in histology and referred to as ‘nests’, which detach from 
the primary site and extend along interstitial tissue gaps. This second mode is observed in 
epithelial cancer and melanoma (21). Interestingly, collective migration is observed in multiple 
stages of the metastasis cascade including clusters of cells circulating in the peripheral blood or 
lymphatic vessels (24-26). The dissemination of collectives of cells has a greater implication for 
cancer metastasis rather than single cells. 
 
1.1.2 Molecular mechanism to regulate collective cell migration 
One of the most distinctive features of collective migration is the formation of leader and 
follower cells. Leader cells localize at the front of the group, where they receive instructive signals 
to guide follower cells at the rear to migrate in the same direction. This process may be regulated 
through chemical or mechanical signaling (27, 28). The existence of the leader and follower cells 
secure front-rear polarity for the entire moving process. Delta-Notch signaling is implicated in 
determining the leader and follower cells as demonstrated in angiogenic (29). An additional 
example of negative feedback loops to inhibit formation of leader cells in neighboring cells is within 
2D sheet migration (28). Interestingly, the fate of leader cells may be transiently determined as 
leader cells and follower cells might dynamically exchange position such as in angiogenic sprouting 
and in the developing mammary gland. The extracellular cues and downstream signaling to specify 
leader and follower cells are probably cell type-specific. Previously described signaling pathways 
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include mitogen-activated protein kinase, focal adhesion kinase, phosphoinositide-3-kinase, Src 
kinases, Notch, and Rho GTPases.  
Once leader and follower cells are specified, individual cells in the group have to respond 
to a plethora of instructive cues from the microenvironment to move as a collective group. These 
signals can be topographic, chemical, or electrical. Topographic cues are consisted of extracellular 
matrix proteins, molecules bound by the ECM or the resident cells within the group. Haptokinesis 
is a topographic guidance in which cells orient their axis and movement along the topography 
provided by the anisotropy of the environment (30). Topography of guiding structures enables 
alignment of adhesion sites in parallel to the substrate, followed by a longitudinal actin cytoskeleton. 
For example, in 1D migration, fibroblasts patterned on a narrow line of adhesive substrate migrate 
in a string-like fashion, discouraging cells to migrate next to each other. Other examples in 3D 
topography guidance include collective groups of cells moving as a continuous sheet at the 
interfaces between muscle fibers or larger nerves and network formed by ECM fibers (31). If 
haptokinesis describes adhesion receptor-dependent migration along an isotropic substrate, 
haptotaxis indicates migration along a gradient of immobilized ligands in the substrate. Cells usually 
orient their migration toward the increasing availability of ligands. However, cell movement may 
also oppose the increasing gradient of ligands depending on the cell type and context (32, 33). 
Leader cells can guide collective migration of the group through sensing the guiding cues, 
depositing or removing the ECMs to alter adhesion sites or releasing or depositing immobilized 
cytokines/chemokines on the ECMs (31, 34). Lastly in topographic guidance, groups of cells also 
respond to the stiffness gradient of the microenvironment, a phenomenon called durotaxis. Positive 
durotaxis or migration towards a stiffer region is previously described in fibroblasts. Similarly, 
sarcoma cell sheets exhibit greater degree of collective migration on a stiffer substrate (35). During 
durotaxis, cells integrate different mechanosensory machineries such as focal adhesion, integrins 
and myosin II-mediated contractility in response to tissue stiffness.   
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In addition to the topographical cues, cell instructive signals also include biochemical and 
electrical signals. In chemical guidance, collective cell migration is influenced by gradient of soluble 
chemical factors, a phenomenon also called chemotaxis. Chemotactic guidance is essential during 
developmental processes but also a powerful tool to direct collective migration in experimental 
systems (36). Gradient of soluble biochemical factors can be generated through intrinsic diffusion 
ability of molecules within tissues or through convection due to interstitial fluid flow or a combination 
of both. Receptor binding and activation by biochemical factors induce and stabilize polarizing cell 
groups to move towards the increasing availability of biochemical cues (37). Chemotaxis is 
generally a paracrine mechanism but also induced by the cells themselves. Cells in a group may 
self-generate a gradient by different mechanisms: releasing chemokine-degrading enzymes that 
diffuse along the cell group and clear chemokines in the rear cells (38), or expressing migration-
enhance factors/receptors in the front and decoy receptors in the rear that bind and internalize the 
chemokines to limit the biological function of the chemokines in rear cells (39, 40). In addition to 
chemoattractant in chemotaxis migration, chemorepulsive cues impose a constraint to direct 
migration away from the cues (41, 42). Such factors include FGF8 and Wint3a, which induce 
mesendodermal cell sheet to migrate away from the primitive streak during gastrulation (43). Lastly, 
electrical guidance also known as galvanotaxis or electrotaxis is probably the least studied in 
collective cell migration. Electrotaxis describes directional migration of cells relative to direct-current 
electric field, which can be generated by cathode and anode (44). It has been shown to influence 
migration of many cell types including fibroblasts, epithelial and endothelial cells, neurons, immune 
cells, and cancer cells (45). Electric field can open voltage-gated ion channels to enable influx of 
ions and downstream signaling through activation of ion transport proteins, and cytoskeletal 
polarization (46, 47). For example, migration-inducing cell surface receptors including EGFR, 
acetylcholine receptor, and integrins were reported to respond to electric fields to locally activate 
PI3K/Akt and MAP/ERK signaling. 
In tissues, there is a plethora of instructive guidance signals including both physical and 
biochemical cues. These cues act parallel to a group of cells. Therefore, migrating collective cells 
7 
 
need to integrate concurrent, potentially cooperative or opposing inputs to make their decision and 
adjust their migrating direction. The integrative inputs may lead to strengthen the cellular cohesion 
of cells within group to encourage collective migration or permit dispersal and transition from 
migration group to single cell migration (48). Therefore, cells within a group need to process and 
prioritize the instructive signals. Particularly interesting is the process of collective migration in 
angiogenesis where endothelial cells not only sprout out from a vessel in a collective manner, they 
also process microenvironment cues to undergo morphogenesis to develop multiple branches and 
well-structured hierarchical networks to support the tissue homeostasis, growth and regeneration. 
 
1.1.3 The morphogenetic process of angiogenesis  
The vasculature develops shortly after gastrulation. Starting as blood islands from 
progenitor cells (hemangioblasts) in the visceral yolk sac, hemangioblasts differentiate into either 
hematopoietic or endothelial cells. The endothelial cells undergo the first phase of blood vessel 
formation in a process called vasculogenesis where they coalesce to form the primitive network of 
the vasculature. A second phase of blood vessel formation, called angiogenesis, begins, as 
endothelial cells from the existing primitive vascular plexus sprout out to form new blood vessels. 
These new blood vessels also undergo extensive remodeling via fusion and regression to finally 
form a fetal vasculature (49). 
 During angiogenesis, in response to various stimuli including biochemical and mechanical, 
some endothelial cells within the capillary walls are selected to become tip cells. These tip cells 
first digest the basement membrane proteins in the blood vessel and extend their cellular 
protrusions, filopodia, into the interstitial tissues to lead the sprouts. Tip cells do not proliferate in 
response to angiogenic cues (50). Though tip cells in zebrafish undergo a single proliferation during 
intersegmental vessel development (51). Other cells follow the tip cells to become stalk cells. Tip 
cells express higher level of VEGFR2 and DLL4 than following stalk cells. However, at any given 
time, stalk cells which express higher level of VEGFR2 and DLL4 can overtake tip cell to resume 
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tip cell position (52). Tip-stalk shuffling is a highly dynamic process. As multicellular sprout 
structures penetrate into the interstitial tissues, stalk cells from the trunk of the sprouts may undergo 
phenotypic transition into tip cells to initiate formation of branches.  
Many steps further are essential to convert a sprout into fully functional blood-carrying 
vessels. For example, sprout extension requires migration of stalk cells. At the same time, stalk 
cells also proliferate to contribute to the extension of sprouts. To form new vascular connections, 
tip cells need to suppress their motile, exploratory behavior as they encounter their targets, which 
are either tips of other sprouts or existing vessels. Strong adhesive interactions between the tip/tip, 
tip/stalk enable connections of 2 sprouts or a sprout to an existing blood vessel. Once connection 
is established, cytoskeletal rearrangement allows opening of the sprouts to form lumen throughout 
the sprouts. Interestingly, existing evidence in zebrafish during intersegmental vessel formation 
suggests the role of fluid shear stress to initiate the formation of lumen within the intersegmental 
vessels (53). Failure of fusion might also help preventing formation of arteriovenous shunts or serve 
as a positive regulation of regression of unnecessary vessels.  
 
Figure 1.1. The morphogenetic processes of angiogenesis (modified and adapted from Alitalo. 
Nature (2006): 8, 464-478). (A) Endothelial cells in the vessels are exposed to pro-angiogenic 
factors and begin to digest the basement membrane protein. (B) The tip cells extend filopodia into 
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the matrix in the direction of pro-angiogenic cues. (C) Tip cells lead the way while stalk cells are 
following. Lumen begins to develop. Tip cell of one sprout can encounter tip cell of another sprout 
during their migration. (D) Fusion of sprouts results in a blood vessel, which is lumenized 
throughout and perfused with blood vessels. Newly formed vessels are eventually mature to with 
deposition of basement membrane proteins. 
 
Angiogenesis undoubtedly plays a critical role during embryo development. Nevertheless, 
dysregulations of angiogenesis in adults can contribute to many diseases. Historically, pathological 
angiogenesis is only implicated in cancer through ground-breaking work by Judah Folkman and 
many other labs to demonstrate that angiogenesis is a hallmark of cancer (54). To support the over-
demanding growth of tumor, cancer cells secrete angiogenic factors to recruit blood vessels to 
supply nutrients and oxygen. These blood vessels then become escaping routes for the cancer 
cells to metastasize and seed distant organs to form secondary tumors. In recent years it has 
become increasingly evident that insufficient or abnormal angiogenesis also contributes to the 
pathogenesis of many more disorders. Another example of pathological disease due to excessive 
angiogenesis is retinopathy in diabetes patients which ultimately leads to blindness. Insufficient 
angiogenesis or damaged endothelium is also implicated in multiple diseases such as Alzheimer 
disease, diabetic neuropathy, atherosclerosis, hypertension, restenosis, Crohn disease, hair loss, 
nephropathy, osteoporosis, and so on (54). 
 
 1.1.4 Molecular mechanism of angiogenesis 
 Because angiogenesis is a critical process, it is tightly regulated by several mechanisms 
including expression of different family members, expression of alternatively spliced variants and 
ligand binding to different receptors. One of the most important molecule that controls blood-vessel 
sprouting is vascular endothelial growth factor A (VEGFA). VEGFA is required for chemotaxis and 
differentiation of endothelial cell precursor cells, endothelial cell proliferation, vasculogenesis, and 
blood vessel remodeling. Alternative splicing of VEGFA generate several variants. Binding of 
VEGFA to the receptor tyrosine kinase VEGFR2 (or KDR or FLK1) promotes downstream signaling 
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to enable angiogenic responses. VEGRF1 (or FLT1), secreted as a soluble receptor, is known to 
act as an antagonist or ligand trap for VEGFA signaling pathway (55, 56). Hypoxia is an important 
stimulus for expansion of the vasculature (57), and VEGF expression is upregulated during hypoxic 
conditions. Specifically, during organ development, cells are first oxygenated by simple diffusion 
until the tissue grows larger than the diffusion limit can permit to support tissue growth. Locally 
hypoxic environment triggers vessel growth through hypoxia-inducible transcription factors (HIFs) 
(57). Loss of a single allele of VEGF can cause vascular defects during embryogenesis (58, 59). A 
25% reduction of VEGF levels impairs spinal cord perfusion and results in motor neuron 
degeneration (60). The role of VEGFB remains to be determined in angiogenesis while VEGFC is 
implicated in controlling lymphangiogenesis. 
 Platelet-derived growth factors share a significant degree of sequence to VEGF but their 
functions are distinct. For instance, PDGF-B is implicated in the maturation of vascular 
development. PDGF-B is expressed on the endothelium while PDGFR is present on vascular 
smooth muscle cells and pericytes. PDGF-B null mice had reduced pericyte coverage on 
capillaries. Similarly, PDGFR-B-null mice had decreased numbers and proliferation of smooth 
muscle cells and pericyte progenitors and most predominantly in the brain, heart, and brown 
adipose tissue (61, 62). Another protein also regulating smooth muscle cell attachment to blood 
vessel is angiopoietin. There are four members of angiopoietins (Ang 1-4) (63). Among these 
Angiopoietin 1 and 2 are the most understood due to their roles in developmental and pathological 
angiogenesis. Angiopoietin signals through Tie2 receptor kinase. Ang2 can induce phosphorylation 
of Tie2 in endothelial cells in autocrine of paracrine manners (64, 65). During angiogenic and 
vascular remodeling, Ang2 is expressed in endothelial cells and contributes to the detachment of 
smooth muscle cells. Genetic knock out of Ang-1 leads to embryonic lethality due to cardiovascular 
abnormalities (66).  
 The superfamily of FGFs and their receptors control a wide range of biological functions 
(67). Among the FGF ligands, bFGF is one of the first discovered angiogenic factors. FGF1 has 
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angiogenic and arteriogenic properties while FGF9 stimulate angiogenesis in bone repair. FGF can 
act on endothelial cells directly or indirectly via activating the secretion of angiogenic factors of 
other cell types (67). For instance, FGF activates secretion of hedgehog, ANG-2, and VEGF-B. 
Aberrant FGF signaling also promotes tumor angiogenesis and mediates the escape of tumor 
vascularization from VEGF-inhibition treatment (68). Interestingly, FGF1 and FGF2 deficiency in 
mice didn’t result in vascular defects and there exists substantial redundancy in the FGF 
superfamily (67). 
 The large TGF-β superfamily also contributes to angiogenesis and vascular malformations. 
Particularly important is the role of ALK1 or endoglin, one of the receptors for TGF-β family. Loss 
of ALK1, ALK5, or TGF-βR-2 leads to arteriovenous malfunctions. Human hereditary hemorrhagic 
telangiectasia or the formation of dilated capillaries is a result of mutation of ALK1 gene (69). TGF-
β signaling plays an important role for differentiation of endothelial cells. TGF-β also promotes 
vascular smooth muscle cell differentiation. As a result, deficiency of ALK1 impairs mural cell 
development (69). However, the effects of TGF-β in angiogenesis remains to be further explored 
due to the inconsistent results whether they promote or inhibit angiogenesis (70). 
 Notch and Wnt signaling pathways also contribute to the formation of blood vessels. 
Studies of tip-stalk cell formation in vessel, particularly, in the retina model indicate the roles of 
NOTCH to mediate the tip-stalk phenotype through DLL4-Notch signaling axis (71). More 
specifically, JAGGED1, a NOTCH ligand is expressed in stalk cells during tip-cell selection by 
disturbing the reciprocal DLL4 and NOTCH signaling from the stalk cell to the tip cell (72).  
Tip-stalk cell selection is a competitive and dynamic process. Besides NOTCH and DLL4, 
endothelial cells also express various types of various WNT ligands and their frizzled receptors that 
can stimulate endothelial cell proliferation. NOTCH activates WNT signaling in proliferating stalk 
cells during vessel branching. WNT also activates NOTCH in a reciprocal-feedback loop (73, 74). 
Gene-inactivation of some of the WNT and Frizzle members in mice such as Wnt2, Wnt5a, Fzd4, 
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and Fzd5 causes vascular defects and combined loss of Wnt7a and Wnt7b impairs angiogenesis 
in the brain and disturb blood brain barrier formation(75). 
 Though less studied in the context of angiogenesis, hepatocyte growth factor (HGF), and 
monocyte chemotactic protein-1 (MCP-1) have also been shown to be involved in angiogenesis. 
HGF, also known as a scatter factor, is a large multidomain protein structurally similar to 
plasminogen with c-met as a receptor with tyrosine kinase activity. HGF is a potent mitogen, and 
morphogen for endothelial cells(76, 77). Administration of HGF as a protein or through adenoviral 
vector promotes angiogenesis without increasing vascular permeability or inflammation (78, 79). 
Combining HGF and VEGF enables more robust proliferative and chemotactic response of 
endothelial cells than either factor alone. Similarly, in 3D collagen gels, neither HGF or VEGF alone 
is sufficient to promote survival or tubulogenesis in endothelial cells, but a combination of the two 
growth factors will promote these responses (80, 81).  
MCP-1 is a key chemokine responsible for trafficking and activation of 
monocytes/macrophages through its receptor CCR2. However, it has also been implicated in 
inflammation and angiogenesis. In fact, administration of exogenous MCP-1 increases 
monocyte/macrophage recruitment, and indirectly results in collateral vessel formation, and 
ultimately blood flow to the ischemic tissue in ischemic hindlimb models (82, 83) and in ischemic 
myocardium (84). Additionally, MCP-1 can also exert direct effects on endothelial cells to trigger 
angiogenesis (85). 
 Besides the growing list of angiogenic proteins (e.g.: VEGF, PDGF, FGF, HGF, MCP-1, 
TGF-β, etc.), recent discoveries also indicate the crucial role of lipids as mediators for 
angiogenesis. Among them, sphingosine-1-phosphate emerges as an important regulator of 
angiogenesis and vessel maturation (86). Sphingosine-1-phosphate (S1P) is a blood-borne lipid 
mediator with pleiotropic biological activities including growth, survival, migration of mammalian 
cells (87). S1P is generated by converting ceramide to sphingosine by the enzyme ceramidase. 
Sphingosine is further converted into S1P by sphingosine kinases (SK1 and SK2). Knockout of 
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either SK1 or SK2 doesn’t affect development of mice as it is fully compensated by the other 
functional enzyme. However, double knockout mice of SK1 and SK2 is embryonic lethal without 
detectable S1P level in the blood stream, suggesting that S1P is mainly generated through SK1 
and SK2 (88).  
The red blood cells are a major source of S1P, but other cell types such as vascular 
endothelial cells, and activated platelets also produce S1P (89-92). S1P binds to a family of five G 
protein-coupled receptors (GPCRs), called S1P1-S1P5 (87). S1P1, S1P2, and S1P3 are widely 
expressed in various tissues and the major receptor subtypes in blood vessels. S1P1 is coupled 
exclusively via Gi to Ras-mitogen activated protein kinase, phosphoinositide 3-kinase/ Akt pathway, 
and phospholipase C pathway, whereas S1P2 and S1P3 are coupled to multiple G proteins to 
activate phospholipase C, Rho pathways and as well as Gi-dependent pathway (86). Endothelial 
cells and vascular smooth muscle cells show distinct patterns of expression of S1P1, S1P2, and 
S1P3. Endothelial cells largely express S1P1 and S1P3, whereas S1P2 is expressed only in certain 
vascular beds (93, 94). S1P3 is abundantly expressed in both in endothelial cells and medial 
smooth muscle cells. S1P3 stimulates nitric oxide synthase and nitric oxide production in 
endothelial cells while it mediates vaso-constriction in smooth muscle cells (95). S1P regulates 
endothelial cell growth, survival, migration, and barrier function (82, 90, 91, 96-98). 
 S1P stimulates angiogenesis mainly through S1P1 and to a lesser extent through S1P3 
(86). Angiogenesis mediated by S1P1 and S1P3 is through activation of Rho GTPase Rac (93, 99-
102)  . S1P1 ablation in mice impairs accumulation of pericytes and smooth muscle cells to the 
blood vessels (103). In contrast to S1P1, S1P2 inhibits Rac activation, endothelial cell migration, 
and tube formation (94). Consistent with in vitro models, S1P2 on retinal endothelial cells exerts an 
inhibitory effect on angiogenesis in avascular areas of the retina (104). Mice null for S1P2 or S1P3 
develop normally without vascular defects, but combinatory deletion of S1P2 and S1P3 results in 
50% lethality but without a defect in smooth muscle cell coverage on vessels. This suggests the 
importance of S1P1 in vascular formation (86). 
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During the processes of angiogenic sprouting, the endothelial cells directly interact with the 
extracellular matrix. Linking the endothelial cells to ECMs are surface receptors such as integrins, 
which are heterodimeric receptors that mediate adhesion to ECM and immunoglobulin superfamily 
molecules (105, 106). Sprouting endothelial cells highly express avb3 and avb5 in tumor, which 
enables engaging of adhesion sites to multiple ECM proteins such as vitronectin, fibrinogen, and 
fibronectin to provide survival and traction for invading endothelial cells. Additionally, other integrins 
have also been reported to play a role in angiogenesis such as a1b1, a2b1, a4b1, a5b1, a9b1, and 
a6b4 (105, 106). Apart from promoting adhesions to ECMs, integrins also regulate angiogenesis 
through other mechanisms. They bind to growth factors (VEGF, FGFs, ANG-1) or their receptors 
(VEGFR2, FGFRs) to activate the signaling and stimulate vessel growth (105, 106).  
A significant part of angiogenic sprouting involves matrix degradation and remodeling 
mediated by enzymatic cleavage of ECMs through proteases. In fact, endothelial tip cells actively 
digest the basement membrane proteins to initiate the invasion into the interstitial tissue. 
Additionally, during branching, proteolytic remodeling of the ECM liberates cell unrestricted 
movement and convert anti-angiogenic peptides of the basement membrane into pro-angiogenic 
peptides. Among the enzymatic proteases, MMPs, a family of over 20 zinc- containing 
endopeptidases, have been shown to play multiple roles in angiogenesis (107). They degrade 
various components of ECMs (108). In addition to degrading ECM components, they also act to 
activate other MMPs and more importantly make available active growth factors and cytokines. For 
instances, MMP degrades insulin-like growth factor (IGF) binding proteins to release active IGFs, 
degrades proteoglycan perlecan in basement membranes to liberate FGFs, and degrade latent 
TGF-β binding proteins to activate active form of TGF-β ligands (109, 110). MMP-9 cleaves the 
pro-inflammatory cytokine IL-8 to increase its activity tenfold, and inactivate the angiogenic inhibitor 
platelet factor-4 (111). MMP activity is regulated by endogenous inhibitors, primarily by the tissue 
inhibitors of metalloproteinases (TIMPs). There are 4 TIMPs (TIMP-1 to -4), which bind tightly to all 
MMPs to regulate their activation. For example, TIMP-2 and TIMP-3 are efficient inhibitors of MT-
MMP2 (112). TIMPs also have additional biological activities independent of their MMP inhibitory 
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activity. For example, in angiogenesis, TIMP-2 can inhibit bFGF-induced endothelial cell 
proliferation (113). 
Last but not least is the role of junctional proteins as regulators of angiogenesis. Cell-cell 
communication is an inherent part of angiogenic sprouting. It is fundamentally important to 
synchronize cell-cell cohesive units in angiogenic sprouting but also regulates angiogenic sprouting 
initiation. Quiescent endothelial cells are growth-arrested through their interconnected junctional 
proteins but angiogenic endothelial cells dissociate their junctions to migrate and invade into the 
tissue. Tight junctional proteins such as claudins, occludins maintain blood brain barriers whereas 
adherent junctions such as VE-cadherins establish cell-cell adhesion during collective migration of 
sprouts (114). Among the adherent junctions, VE-cadherin is probably the most studied. Loss of 
VE-cadherin does not prevent development of vessels but causes defects in vascular remodeling 
and integrity (54). VE-cadherin is also required to localize CD34 to cell-cell contact for lumen 
formation (115). Localization of VE-cadherin at filopodia allows tip cells to establish new contacts 
with cells on outreaching sprouts to enable anastomosis between vessels (70). 
 
 1.1.5 Models to study angiogenesis 
 Vascular dysfunctions causally contribute to many diseases, including but not limited to 
cardiovascular diseases. The endothelium also plays a critical role in the pathobiology of illnesses. 
Angiogenesis is necessary to form new blood vessels in ischemic tissues or wounded tissues. 
However, excessive angiogenesis may be harmful in disease development such as in cancer, 
diabetic retinopathy, atheroma growth or the expansion of vasa vasorum (116). Recent studies also 
suggest that the endothelium secret angiocrine factors to balance between tissue regeneration and 
fibrosis after injury. Increasing evidence suggests even though endothelial cells are essential 
players of neovascularization, their cross-talks to other stromal cells such as pericytes, vascular 
smooth muscle cells, and immune cells are also very important to regulate the processes of 
neovascularization. Simple in vitro models possess some advantages to examine the many 
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processes of angiogenesis such as lumen formation, biochemical and mechanical interactions in 
high resolution imaging. However, in vivo models are also necessary to study the more complex 
interactions that enable functional and hierarchical blood vessel networks. Therefore, it is essential 
to utilize both in vitro and in vivo angiogenesis models to recapitulate angiogenesis in different 
stages of development and in different contexts (116). 
a) In vivo models of developmental angiogenesis 
In all vertebrates, blood vessels form through successive steps of vasculogenesis and 
angiogenesis. Upon differentiation of angioblasts, the endothelial cell precursors coalesce to form 
a primitive plexus of the vasculature. Expansion of the initial network of vessels through 
angiogenesis develops into fully functional and blood perfused networks of vessels. Immediately 
or during the vascular network expansions, remodeling of the vessels also occurs to prevent 
excessive formation of vessels and enable formation of mature vessels with mural cell coverage. 
A larger number of signaling pathways have been described to regulate vascular network formation 
during development (117) using various in vivo models of developmental angiogenesis including 
mouse embryonic hindbrain, postnatal retina, avian embryos of chick and quail, and avian models 
of zebrafish and Xenopus. 
Mouse hindbrain is vascularized before birth (118). The vasculature commences as 
vessels sprout into the hindbrain from a perineural vascular plexus at E9.5. First, these vessels 
grow perpendicular to the hindbrain surface toward the ventricular zone and then change direction 
to be parallel with the ventricular hindbrain surface and later anastomose with each other. This 
model is particularly important for the spatiotemporal analysis of organ vasculature due to their 
utilities for whole-mount staining and high-resolution imaging. Genetic manipulations are also 
available and more powerful when used with Cre-recombinase technology to study the roles of 
genes that might be lethal before birth of the embryos. 
In contrast to the mouse hindbrain vasculature, the retinal vasculature is only formed after 
birth (119, 120). Right on the day of birth, the vessels from the optic nerve head sprout 
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perpendicularly over the surface of the retina on a network of astrocytes. As the vascular network 
continues to advance at the front, the rear vasculature begins to remodel to form arteries and veins. 
Further recruitment of pericytes and smooth muscle cells encompasses the blood vessel to form 
mature vasculature. The primary vascular plexus is completed by day 9 postnatal. However, an 
additional 10 days is required for the remodeling and maturation of the vessels. One of the major 
advantages of the retinal model is its 2D structure, enabling high resolution imaging and reliable 
quantification of vascular migration and angiogenic sprouting. Additional advantage is that vascular 
formation is postnatal, which can be more easily influenced by environmental factors than hindbrain 
angiogenesis, which occurs in the utero. However, it is less suitable to quantify network density 
and vessel calibers as sprouting and remodeling are temporally overlapping, especially at the 
vessels in the rear of the network (116). 
Avian models of angiogenesis include chick and quail. The hallmark advantage of this 
model is that the animal development is within an eggshell, which may be used as a culture dish 
by creating a window for visual inspections and mounted on a microscope stage to monitor for 
extended periods of time. The larger size of the embryos also allows easy grafting of the tissues 
between different embryos. Previous work on grafting brain endothelial cells into liver shows the 
plasticity of brain endothelial cells to adapt to the liver environment by losing their blood brain barrier 
properties to adopt fenestrations (116). The most popular choice of experimental setup within the 
avian model is the chorioallantois membrane (CAM). The CAM is a highly vascularized 
extraembryonic appendage that provides nutrients and oxygen to the chick embryo. CAM is 
situated right beneath the eggshell, making it accessible to monitor the growth of vessels. Although 
CAM has been widely used to identify pro- and anti-angiogenic factors, validating the relevance of 
this model to intraembryonic angiogenesis remain a technical challenge (116). 
Complimentary to the mentioned above in vivo models of developmental angiogenesis is 
the aquatic model, which includes zebrafish and Xenopus. The hallmark advantage of both of these 
animal models is their semi-transparency, which makes it attractive for high resolution imaging. 
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Additionally, when coupled with in vivo labeling of endothelial cells, these models enable 
noninvasive studies of endothelial cell dynamics during angiogenesis. In the zebrafish model, 
specified angioblasts originated in the posterior lateral plate mesoderm migrate toward the midline 
to form a primordial vascular cord or precursor of the dorsal aorta (DA) and posterior cardinal vein 
(PCV) (121). Once the major axial vessels are established in the trunk, sprouting angiogenesis 
occurs. Bilateral sprouts branch off from the DA, led by migrating tip cells and follower proliferative 
stalk cells. These sprouts later anastomose and form arterial intersomitic vessels (ISVs). A 
secondary sprouting occurs from the PCV between 30 and 50hrs after fertilization. Half of these 
sprouts form the lymphatic vessels while the other half connect to the arterial ISVs, which lose their 
original connection with the DA to become venous ISVs and complete the circulation in the trunk 
of the zebrafish. Unlike the zebrafish, Xenopus form 1 DA and 2 paired PCVs, which resemble 
more closely to higher vertebrates, where DA and PCV each develop from a pair of vessels that 
later fuse to form a single DA and single PCV (122). Unlike zebrafish, ISVs emerge from both the 
DA and PCV such that there is a pair of arterial ISV and venous ISV at each intersomitic junction, 
which is more similar to mammals. ISVs reach the dorsal side of the trunk and anastomose to form 
the dorsal longitudinal anastomosing vessel (DLAV), which connects to the PCV near the head. 
Additional sprouting of capillaries is required to cover all the tail area by stage 46 (123).  
 
b) Models of adult angiogenesis 
Postnatal angiogenesis is mostly associated with tissue or organ growth. In some cases, 
postnatal angiogenesis is caused by reproductive demands or pathologies such as in cancer. 
Additionally, adult angiogenesis also occurs as the tissue or organ undergoes repairing processes 
from injury or vascular occlusion.  
One of the most visual and physiological assays for adult angiogenesis is the cutaneous 
wound assay. Tissue repair requires extensive cell proliferation, matrix deposition, and clearance 
of cell debris, which also demands heavily nutrients from the blood vessels. Thus, new blood 
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vessels are formed through angiogenesis to increase vascular density. Once the tissue is complete, 
vascular density returns to its normal level. Vessel density from time of injury to time of complete 
healing follows a bell-shape curve, with highest vessel density during the wound healing process. 
Although cutaneous wound healing is a robust model of adult angiogenesis that can be used in 
mice, rats, pigs, dogs, and primates, there are caveats that need to be considered. The extent of 
vascularization is highly dependent on the animal age. The angiogenesis process also relies on 
the blood coagulation system and inflammatory cells, which may complicate the mechanical 
understanding of the process (116). 
In addition to wound healing assay, there are Matrigel plug assay and angioreactors. 
Matrigel plug is an easy angiogenic setup, in which an injection of Matrigel with or without growth 
factor supplement is administered subcutaneously into mice. Analysis is followed between 7-14 
days post injection. Some analyses include vessel density and hemoglobin contents in the excised 
plugs. Additional information from the cellular content can also be quantified after fixation of the 
excised plugs. Some disadvantages of this model include inconsistency between different Matrigel 
plugs even within one animal. The ingrowth vessels in Matrigel plugs are often leaky and less 
mature without pericyte coverage, limiting the model to study the remodeling process of the 
vasculature (124). Similarly, to the Matrigel plug assay, angioreactors are implanted silicon 
cylinders that contain premixed volume of matrix with or without supplementary growth factors. 
Angioreactors are often implanted subcutaneously in the dorsal flank of mice (125). Similar 
analyses to Matrigel plug assay are also performed in the angioreactors.  
c) In vitro models of angiogenesis 
In vivo models of angiogenesis may better reflect the complex processes of 
neovascularization and often provide important assessments of therapeutic angiogenic agents in 
living animals. However, in vivo models require technical expertise, highly complex, time 
consuming and relatively expensive (126). Additionally, neovascularization in living organisms is 
not an isolated process but involves multiple cell types, as well as biochemical and mechanical 
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cues within the environment. Ultimately, these factors may complicate understanding of biological 
mechanisms of angiogenesis. As a result, in vitro models of angiogenesis become a valuable tool 
to quickly assess the effects of therapeutic agents, but also allow high resolution imaging and 
detailed mechanistic studies. There exist various in vitro models of angiogenesis which assess 
different aspect of angiogenesis including: migration, proliferation, 2D network formation, and 3D 
sprouting. 
Migration is one important aspect of angiogenesis sprouting. To assess migration, scratch 
wound assay has been employed due to their simple, quick, and inexpensive properties. Simply, 
endothelial cells are grown into a confluent monolayer and wounded by using a tip, needle or cell 
scrapper (127). The rate and extent of endothelial cell migration towards the ‘wounded’ area can 
be microscopically monitored over several hours until the assay complete around 8-18hours. 
Though wound healing assay is easy and quickly adapted by many labs, there are disadvantages 
to the models: difficulty in reproducing the scratched area of equal size, variability among wells due 
to initial cell confluence, mechanical damage to the endothelial cells when creating the wounds with 
sharp objects, and incapability to separate cell migration from cell spreading and proliferation (127). 
Several modifications have been made such as introduction of a fence or barrier instead of using 
the sharp objects to improve the reproducibility. However, cell spreading and proliferation are still 
inseparable from migration. Additional cell migration model also includes Boyden chamber to study 
cell migration towards a stimulus, but this set up inherently lacks the capability to be used for high 
resolution imaging. 
The effects of angiogenic factors on endothelial cell proliferation can be assessed by 
different methods more suitable than wound healing assay. Endothelial cells are often starved in 
serum-free or low serum medium and subsequently stimulated with stimuli. The most common and 
inexpensive means to evaluate proliferation is by using hemocytometer in conjunction with cell-
viability dye. An additional method based on the incorporation of DNA-binding dyes, such as BrdU, 
can also be used to visualize proliferation cells when cells are in S phase of the cell cycle. Metabolic 
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activity can also be correlated with cell proliferation and its activity can be examined using 
colorimetric assays. However, in some cases, an increase in metabolic demand doesn’t always 
correlate with cell proliferation (128).  
A commonly used in vitro angiogenic assay is tube formation on Matrigel in which 
endothelial cells are plated on a 2D surface of Matrigel, which is highly enriched in laminin (129). 
Quickly after 4-16hrs, endothelial cells organize into tube-like network on the Matrigel surface. 
Images can be taken in different areas of wells to quantify tube length, number of sprouts, number 
of branches, and number of ring structures. This assay can be used quickly to assess the potential 
therapeutic agents for angiogenesis. However, it is still under dispute whether these tube-like 
structures resemble capillaries with lumen in angiogenesis. Moreover, many other non-endothelial 
cell types such as fibroblast, vascular smooth muscle cells, and cancer cells may also form similar 
structures when plated on Matrigel, suggesting that this assay describes a competitive cell-cell 
versus cell-matrix interactions and hence, not specific to endothelial cells. 
To mimic the fundamental properties of endothelial cells to form lumen in 3D matrices, 
other models have been employed but the most common one is the endothelial cell tubulogenesis 
model. Endothelial cells are seeded in 3D collagen or fibrin matrices (130, 131) to allow them to 
assemble and align over time to form lumenized tubes. Lumen can be demonstrated by cross-
sections of cultures, confocal microscopy or transmission electron microscopy. Interestingly, this 
model also describes formation of tunnel spaces in the ECMs, vascular guidance channels, through 
MT1-MMP. These channels enable motility of endothelial cells, matrix remodeling, and recruitment 
of mural cells to the abluminal surface. Attachment of mural cells also increase basement 
membrane protein depositions interior of the guidance channels (34, 132, 133).  
Even though tubulogenesis recapitulate some of the intrinsic properties of endothelial cells 
such as tubule, lumen formation and recruitment of pericytes, this model generally lacks the initial 
invasion of endothelial cells. Therefore, a common strategy to seed endothelial cells on a 2D 
collagen matrix and allows them to invade inwards into the gel under guidance of angiogenic factors 
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with or without pericytes (34). Aggregates of spheroids have also been embedded inside matrices 
to mimic sprouting angiogenesis. Alternatively, endothelial cells are also seeded to coat surface of 
carrier beads, which are embedded into fibrin gels with the presence of human lung fibroblasts to 
enable endothelial cells to migrate outward from the carrier beads to form 3D lumenized sprout 
structures (134). Endothelial cell migration, and dynamic sprouting can be monitored with bright 
field contrast in real time. Sprout length, branches, lumen formation, and anastomoses can be 
assessed under this model. However, one of the disadvantages of this model is the presence of 
thick collagen matrices that limits the capability to perform high resolution imaging. 
A more recent advance of in vitro model of angiogenesis has been the utilization of 
microfluidic devices in which vascular sprouting occurs in the presence of fluid flow. Transparency 
of materials to make such microfluidic devices also enables higher resolution imaging. Though 
these microfluidic platforms are sophisticated, they are fabricated based on a simplistic design in 
which two square/rectangular channels are generated by casting off a mold. These rectangular 
channels are comprised of 3 sides made from inert polydimethylsiloxane (PDMS) whereas the 4 th 
side is a collagen or fibrin matrix wall where endothelial cells adhere and spread to form a 
monolayer. The other rectangular channel is enriched with angiogenic factors to enable migration 
of the endothelial cells into the collagen or fibrin matrix (135). Interestingly, to support the hydrogel, 
additional structural PDMS posts are interspersed inside the hydrogel, which create artificial stiff 
surface and may influence the migration of endothelial cells. 
  
1.1.6 Rho GTPases as regulators for cell migration and cell-cell adhesion and angiogenesis 
 Cells in multicellular animals not only migrate through the extracellular matrix but also on 
top of each other, between each other, and even through each other (136). There are various 
examples to illustrate such processes. For instance, immune cells migrate on endothelial cells, 
adhere and finally migrate through the endothelium to get to the inflamed tissues (137). In order to 
move, cells have to extend their protrusions and generate forces to advance their body forward. 
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Many different molecules and signaling pathways coordinate cell migration especially collective cell 
migration. Particularly important in cell migration is the role of actin cytoskeleton and regulators of 
actin dynamics. Angiogenic sprouting involves extensive remodeling and arrangement of actin 
cytoskeletons to enable a dynamic process between cell-cell within the multicellular sprout 
structures. Therefore, actin cytoskeleton and regulators of actin dynamics are expected to influence 
the morphogenetic processes of angiogenesis. 
 Among the regulators of actin dynamics are Rho GTPases. Mammalian Rho GTPases 
comprise a family of 20 molecules. Most Rho GTPases switch between an active GTP-bound state 
to an inactive GDP-bound state. The activation of Rho GTPases are controlled by three sets of 
proteins: guanine nucleotide-exchange factors (GEFs), GTPase-activating proteins (GAPs), and 
guanine nucleotide-dissociation inhibitors (GDIs) (138). GEFs catalyze the binding of GTP while 
GAPs deactivate the Rho GTPases. GDIs modulate Rho GTPases by sequestration of Rho 
GTPases in GDP-bound or GTP-bound states (139-141). Upon activation, Rho GTPases interact 
with their downstream targets to stimulate a variety of biological activities: cell migration, cell 
division, adhesion, vesicle transport, microtubule dynamics, morphogenesis, neuronal 
development, cell-cycle progression and gene expression (142).   
Although there are many Rho GTPases, the three most studied members are RhoA, Rac1, 
and Cdc42. The most extensively studied RhoA effectors are the serine/threonine Rho-associated 
kinases (ROCKs), which are transported to the plasma membrane upon association with active 
RhoA (143). ROCKs is best known to regulate actomyosin contractility via phosphorylation of 
myosin light chain. The most well studied effector of Rac1 and Cdc42 is p21-activated kinase family 
of serine/threonine kinases. 
 Most studies within the context of RhoA signaling in angiogenesis have focused upstream 
of myosin through targeting RhoA and ROCK. Interestingly, these experiments obtain inconsistent 
results. For example, in studies of VEGF-induced, tumor-induced, or hypoxia-stimulated 
angiogenesis in vivo, RhoA/ROCK signaling appeared to enhance angiogenesis in some cases 
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(144, 145) but inhibit in others (146, 147). In agreement with in vivo studies, in vitro studies of 
RhoA/ROCK/Myosin II activity also exhibit inconsistent results. For instances, ROCK activity 
appeared to suppress invasion into 3D matrix (148) but it increased 2D migration and tube 
formation (149). This suggests the complicated role of RhoA to regulate angiogenesis. While RhoA 
regulates contractility, Rac proteins is most known to modulate lamellipodia and membrane ruffling 
formation (142). There are three Rac isoforms: Rac1, Rac2, and Rac3. Rac1 is probably the best 
studied among the three isoforms (138). Rac1 is ubiquitously expressed and involved in migration 
of pericytes, vascular smooth muscle cells, and macrophages (103, 150, 151), all of which can 
contribute to vessel development and angiogenesis (152, 153). In fact, conditional knockout of 
Rac1 suggest its crucial role for vascular development in the embryo. Interestingly and similarly to 
the RhoA, some study suggests the positive regulation of Rac1 (154) while some other study 
indicate the indispensable Rac1 in the context of tumor angiogenesis (155). 
The role of Cdc42 in angiogenesis has not been well described as compared to the roles 
of RhoA and Rac1 in angiogenesis. Cdc42 protein was first identified in Saccharomyces cerevisiae 
as a cell-cycle mutant where loss of Cdc42 inhibits budding and mating (156). A myriad of genetic 
knockout studies of Cdc42 demonstrate the importance of Cdc42 during development. For 
example, Cdc42 global knockout is embryonic lethal while conditional knockout of Cdc42 under 
different specific promoters results into different effects in the organism development depending on 
the affected cell types: defect in homing and retention of hematopoietic cells in bone marrow under 
Mx1-Cre, disturbance fate determination of apical neural progenitor cells under Emx1-Cre, loss of 
polarity in telencephalic neuroepithelium under Foxg1-Cre, hair loss in keratinocytes under K5-Cre, 
defect in axonogenesis in the brain under Nestin-Cre, and carcinoma development in the 
hepatocytes under Alb-Cre (157-159). It plays an essential role to cellular polarity (156) both in 
yeast and mammalian cells. Many studies of cellular polarization have focused on the epithelial 
sheet formation during which cells polarize to form distinct apical and baso-lateral surfaces between 
cell-matrix and cell-cell contacts. This polarization is initialized by adhesion protein such as nectin 
and E-cadherin (160), whose engagement also induces Cdc42 activation (161-163). Additionally, 
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in the context of cell migration in chemotaxis, individual cells also polarize in response to 
chemotactic soluble factors to generate front and rear ends in order to migrate towards the higher 
concentration of chemotactic factors. Cdc42 is shown to regulate this polarizing axis during cell 
migration. Dominant-negative Cdc42 mutants in neutrophils disturb polarization of the cells through 
generating unstable pseudopods while constitutively active Cdc42 blocks any changes in 
morphology (164).  
Another well-known biological activity of Cdc42 is to regulate formation of filopodia. 
Filopodia are finger-like actin-rich protrusions generated by the cells, often at the front of the cells 
during cell migration. They contain parallel bundles of filamentous actin and are thought to be 
important for probing the environment. More specifically, in angiogenesis, filopodia are present 
mostly in tip cells. In many cell types, both constitutively and dominant-negative Cdc42 affect the 
formation of highly dynamic filopodial extensions. Though it is important for cell migration, some 
study also suggests filopodia are dispensable for migrating tip cells in formation of intersomitic 
vessels in zebrafish model (165). Several downstream targets of Cdc42 in filopodia formations 
have been identified: Wiskott-Aldrich syndrome protein, actin-related protein-2/3, insulin-receptor 
substrate p53, and Diaphanous proteins (157, 166, 167).  
In regard to angiogenesis, there have been fewer studies to address the role of Cdc42 in 
angiogenesis. However, there have been studies to address the role of Cdc42 in lumen formations 
in tubulogenesis which appears to capture vasculogenesis rather than angiogenesis. In these 
studies, endothelial cells form intracellular vacuoles through pinocytosis. These vacuoles coalesce 
to form the lumen between endothelial cells. This process is largely driven by Rac1 and Cdc42 as 
both Rac1 and Cdc42 localize to the vacuole membranes during formation of lumen. Silencing 
Rac1 or Cdc42 inhibits vacuole formation and thus lumen formation. Downstream signaling 
molecules include WASP, PAK, Par3, Par6, and protein kinase C (168). Assessing the roles of 
Cdc42 in angiogenesis in vivo has been challenging due to embryonic lethality before E6.5 which 
occurs before formation of the vasculature (169). A recent study attempts to address the 
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vasculature defect in a conditional knockout Cdc42 in Tie2-Cre mice. The authors demonstrate that 
lack of Cdc42 in endothelial cells impairs migration and survival of endothelial cells but not cell 
cycle progression and ultimately results in defects in the vasculature. Additionally, the role of 
ADAM17 to mediate VEGFR2 shedding is also linked to conditional knock out of Cdc42 in 
endothelial cells, suggesting the role of Cdc42 in mediating VEGF signal transduction in vivo (170). 
 
1.2 Pathology of pancreatic cancer and vascular invasion in pancreatic cancer 
 1.2.1 Pancreatic adenocarcinoma 
Pancreatic cancer is currently the fourth leading cause of death among all cancers in the 
United States. With a 5-year survival rate well below 7% and a median survival of less than 6 
months, pancreatic cancer has become the most devastating cancer of all (171). In addition to that, 
due to a lack of unique symptoms and limitation in diagnosis, most patients are often diagnosed 
when they are in the advanced stages. Once diagnosed with pancreatic cancer, surgery and 
chemotherapy are possible options. However, for the 15-20% of patients who undergo potentially 
curative resection, 80% patients relapsed, resulting a 20% survival after 5 years (171). 
Improvement in survival has been minimal even when chemotherapy and/or radiotherapy are 
employed on patients who have had surgery due to the fact that the cancer itself is intensely 
resistant to chemotherapeutic drugs (172). 
The normal pancreas is consisted of digestive enzyme-secreting acinar cells, bicarbonate-
secreting ductal cells, centro-acinar that are located geographically at the transition between acinar 
and ductal cells, hormone-secreting endocrine islet cells, and relatively inactive stellate cells. 
However, the majority of malignant neoplasms of the pancreas are ductal adenocarcinomas. It has 
been thought that the origin of pancreatic cancer cells is from ductal cells (173). However, recent 
study pointed out that the Kras-mutated acinar cells were more capable of giving rise to pancreatic 
cancer as compared to Kras-mutated ductal cells and Kras-mutated centro-acinar cells (174). 
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Some less common pancreatic neoplasms include neuroendocrine tumors (arising from cells 
secreting insulin or glucagon), colloid carcinomas, pancreatoblastomas, and solid-pseudopapillary 
neoplasms (172). 
 Pancreatic cancer most frequently originates from pancreatic intraepithelial neoplasia 
(PanIN), but can also arise from larger precursor lesions such as intraductal papillary mucinous 
neoplasms (IPMNs) and mucinous cystic neoplasms. The molecular pathology of pancreatic 
cancer is dominated by constitutively active mutant Kras (>90%) (175). Additionally, inactivating 
mutations of TP53, CDKN2A, and SMAD4 are accounted for 50-80% of pancreatic cancers. Other 
genes such as ARID1A, MLL3, and TGF-ΒR2 are mutated in ~10% of all cases (176). In addition 
to the mutations acquired as the disease progresses, pancreatic cancers also display an aberrant 
autocrine and paracrine signaling cascades that ultimately support cancer cell proliferation, 
migration, invasion and metastasis. Some of which include TGFα, IGF1, FGFs, HGF, and their 
respective tyrosine kinase receptors EGFR, ERBB2, FGFRs, and HGFR. These signaling 
cascades are active in conjunction with anti-apoptotic and pro-survival pathway such as signal 
transducer and activator of transcription 3 (STAT3), nuclear factor-kB (NF-kB), and AKT (176). 
 Pancreatic cancers have also been characterized with an abundant and dense collagenous 
stroma (desmoplasia), resulting in a considerable hypoxic environment for tumor cells (177). The 
dense stroma of pancreatic cancer is comprised of many extracellular matrix proteins (ECMs), such 
as collagens, fibronectin, and laminins, as well as non-collagenous proteins such as glycoproteins, 
proteoglycan, and glycosaminoglycans (178). Tightly bound to the ECMs are factors together with 
osteopontin, periostin, and serine protein acidic and rich in cysteine that mediate interactions 
between the stromal cells and pancreatic cancer cells. Stromal cells include pancreatic stellate 
cells (believed to produce collagenous matrix and often been referred to as cancer-associated 
fibroblasts), infiltrating immune cells, endothelial cells, and neuronal cells. Immune cells within the 
tumors include T cells with majority being CD4+ regulatory T cells, myeloid-derived suppressor 
cells, macrophages and mast cells. Interestingly, the majority of infiltrating immune cells is 
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immunosuppressive phenotype even during earliest stages of the cancer (179). Because of the 
dense stromal environment, successful drugs delivery has been a challenge in both in vivo mouse 
models and in clinical settings. Although there has been substantial evidence of facilitatory role of 
stromal pancreatic stellate cells in tumor growth and metastasis, recent studies (using genetic 
techniques to deplete myofibroblasts numbers and functions) suggested stromal has a protective 
role in pancreatic cancer (180). These discrepancies indicate that the influence of stroma in 
pancreatic cancer might be context- and time-dependent. 
 Models of pancreatic cancer such as traditional cell lines, xenograft models, genetically 
engineered mouse models (GEMM), and organoid cultures have greatly advanced the knowledge 
and biology of pancreatic cancer (181). Traditional cell lines derived from human patients have 
been used together with the immunocompromised mouse in xenograft models remain widely used 
for initial screening of drugs or to understand the mechanisms in cell biology of pancreatic ductal 
adenocarcinoma cancer (PDAC). However, one of the key shortcomings of using cell lines and 
xenograft model is that the tumors from xenografts often lack the characteristics of the PDAC tumor 
environment such stromal cells and ECMs (181). To address many of the key weaknesses of the 
xenograft approach, GEMM was developed to recapitulate the tumor progression in PDAC. The 
most common GEMM is activating mutation in KRAS, followed by inactivating mutations in 
CDKN2A, TP53, and SMAD4 (182). The first successful engineering model that helped to launch 
the field was LSL-KrasG12D in combination of Cre recombinase technology to target the PDX 
promoter in pancreatic epithelial cells. KRasG12D mice (KC) bearing an activating Kras mutation 
appeared to have a median survival of 1 year and developed a spectrum of pre-invasive ducal 
lesions that mirror human PanIN. Upon aging, KC mice spontaneously develop primary and 
metastatic PDAC. However, not all KC mice develop PDAC. Therefore, to promote a rapid onset 
of PDAC, additional inactivating mutations in TP53, CDKN2A, or SMAD4 have been successfully 
implemented (183, 184). Among these, KC mice with mutated TP53 (KPC mice) possess properties 
that resemble human pancreatic cancer such as hypovascular, dense stroma, and 
chemo/radiotherapy-resistance (185, 186). 
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 Interestingly, organoid cultures of human and mouse pancreatic cancer have been 
described. Inspired from previously reported techniques to culture intestinal, gastric, colon 
carcinoma, hepatic, pancreatic, and prostatic organoids, pancreatic cancer organoids can be 
readily established from small biopsy specimens to obtain tumor cells. These tumor fragments of 
ductal cells were then embedded in 3D Matrigel. The 3D culture conditions to culture patient-
derived organoids enables personalized medicine and also serves as an important model to identify 
gene drivers and molecular pathways involved in PDAC progression (187). 
1.2.2 TGF-β signaling in cancer and in pancreatic cancer 
 The transforming growth factor-beta (TGF-β) was first discovered in 1983 as it possessed 
the ability to transform rat fibroblast (188). It is an important cytokine that is implicated in an 
extraordinary range of biological processes. The nomenclature, structure, receptor types, ligand 
interactions, and variability in signaling molecules make TGF-β and its partners an extremely 
complex group of proteins to study. TGF-β is a member of a large family of structurally related 
polypeptide growth factors, with each cytokine capable of governing numerous cellular processes. 
The proteins in TGF-β family are divided into 2 main branches: the BMP/GDF/MIS and TGF-
β/Activin/Nodal branches, based on their sequence homology and the specific signaling cascade 
that they participate in (189). In mammals, there are three distinct TGF-β isoforms (TGF-β1, TGF-
β2, and TGF-β3), Although, they are encoded by different genes and expressed in a tissue-specific 
and developmentally regulated manner, they signal through the same receptor-signaling systems. 
These isoforms are expressed in epithelial, endothelial, hematopoietic, and mesenchymal cells.   
Among these isoforms, TGF-β1 is the most abundant and universally expressed across 
many tissues (189). TGF-β1 is secreted into the extracellular matrix as a 25kDa molecule which is 
subsequently bound to one of several latent TGF-β1-binding proteins (LTBPs) to constitute a 
complex comprising of a dimer of TGF-β and LTBP (190, 191). The LTBP and TGF-β complexes 
not only stabilize TGF-β1 but also sequester the molecule within the ECM. Though it is 
hypothesized that activation of TGF-β1 from the complexes require subsequent proteolytic 
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enzymes to release the bioactive TGF-β1, integrins have been shown to activate TGF-β1 from its 
complexes as well (192). Once released from the complexes, TGF-β1 dimers initiate its signaling 
via binding to its appropriate receptors. 
There are two high affinity receptors for TGF-β ligands: TGF-β receptor type I, TGF-β 
receptor type II. The mechanism of signaling for all the ligands is fundamentally the same. Each 
ligand requires two types of receptors (type I and type II). For some ligands, additional co-receptors 
are required for optimal binding. Once the ligands bound to the receptor complexes, the 
constitutively active type II receptor phosphorylates the type I receptor on several serines and 
threonines in a highly conserved glycine- and serine-rich domain, close to the membrane-spanning 
region. This phosphorylation then activates the type I receptor kinases and allows binding site for 
the downstream substrates (193), the receptor-regulated SMADs (R-SMADs). 
Although SMAD proteins are not the only molecules that can transduce TGF-β superfamily 
signals to the nucleus, they are the best understood. There are eight vertebrate SMADs: SMAD1 
to SMAD8 (194), which are classified into 3 groups: R-SMAD (SMAD1, SMAD2, SMAD3, SMAD5, 
and SMAD8), co-SMAD (SMAD4), and I-SMADs (SMAD6, SMAD7). A traditional view of TGF-β 
superfamily is that BMPs and GDFs signal through SMAD1, SMAD5, and SMAD8 whereas TGF-
βs, Activins, and NODAL signal through SMAD2 and SMAD3. However, TGF-βs have also been 
shown to phosphorylate SMAD1 and SMAD5 in addition to SMAD2 and SMAD2 in many cell types 
depending on the context (195-198). The mechanism of signaling for all the TGF-β family ligands 
is fundamentally similar.  
Receptor-mediated phosphorylation allows R-SMADs to form heteromeric complexes with 
SMAD4. SMAD4 occupies a central position in the signaling pathways downstream of all the 
ligands. SMAD4 is required by many ligand-mediated responses but not all. The activated SMAD 
complexes are then transported into the nucleus to bind DNA and transcription factors to express 
multiple genes. In the nucleus, SMAD phosphatases also dephosphorylate activated R-SMADs to 
allow them to be exported into the cytoplasm. SMAD-pathways are also subject to numerous levels 
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of regulations. TGF-β superfamily pathways are also modulated by other signaling pathways. For 
example, R-SMADs are activated by growth factors-mediated through MAPKs, glycogen synthase 
kinase 3b (GSK3b), and cyclin-dependent kinases (CDKs). Interestingly, the TGF-β superfamily 
pathways are also known to antagonize each other – for example, GDF3 directly inhibits BMP 
signaling (199). 
 Although inhibition of cellular proliferation is one of the primary functions of TGF-β 
signaling pathway, numerous other contributions have been identified such as embryogenesis, 
differentiation, apoptosis, angiogenesis, immunosuppression, and wound healing. Because TGF-β 
regulates multiple biological processes, any aberration of its normal activities including its normal 
signaling partners in the TGF-β signaling cascade can have a wide-range pathological 
consequences. In fact, pathogenesis and progression of many cancers such as pancreas, colon, 
breast, melanoma, prostate, gastric, neuroendocrine, genecologic, skin and nervous system have 
been attributed to the disruption of normal TGF-β signaling (200). Interestingly, though TGF-β acts 
to inhibit proliferation, thus a tumor growth suppressor, some human malignancies can subvert 
TGF-β for their own purposes. These cancers overexpress TGF-β ligands, which eventually leads 
to loss of normal growth inhibitory response to TGF-β and advances metastasis and decreased 
survival. Therefore, TGF-β plays a paradoxical role as it is both classified as a tumor suppressor 
and as a tumor promoter in many cancers including pancreatic cancer (201). 
In pancreatic cancers, tumor cells have lost their tumor suppressive effects of TGF-β1 and 
several mutations of the TGF-β transduction pathway have been well described. The mutation or 
deletion of the common partner SMAD4 is probably the most well-characterized. SMAD4 or DPC4 
was one of the first novel tumor suppressors identified in pancreatic carcinomas (202). 
Approximately 30% of all pancreatic cancers shows a homozygous deletion of DPC4. DPC4 is 
inactivated in another 20% of pancreatic cancers. Almost in 90% of pancreatic tumors, there is an 
allelic loss of DPC4 chromosome. Mutations in DPC4 are within either the MH1 or most commonly 
the MH2 domain of the SMAD4 protein. These mutations are consisted of missense, nonsense or 
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frameshift mutations. Some of the arginine mutations in the MH1 domain lead to rapid degradation 
of SMAD4 as compared to wild type. Approximately, 50-90% of patients have SMAD4 alterations 
that diminish cell cycle control (202). 
Additionally, human TGF-β receptors have also been found to have certain inactivating 
mutations in many cancers such as colon, gastric, liver, breast and pancreatic cancer. Although 
mutations in TGF-βRII are observed in the majority (70-90%) of colorectal cancers, it is less 
frequently observed in pancreatic cancer, accounting for 4-7% of pancreatic cancers (203). 
Similarly, mutations in TGF-βRI accounts for 5% of cases. Some pancreatic cancers acquire 
resistance to normal inhibitory-growth of TGF-β by expressing low level of TGF-βRI, which can be 
restored by transducing cells with functional TGF-βRI (204).  
1.2.3 Roles of other TGF-β superfamily members in cancers 
The TGF-β superfamily comprises the TGF-βs, Activins, NODAL, bone morphogenetic 
proteins (BMPs), growth and differentiation factors (GDFs), and anti-Mullerian hormone (AMH). 
Over the past three decades, much emphasis has been given to the TGF-βs in cancer. However, 
increasing evidence of other TGF-βs superfamily members to contribute to cancer progression has 
upsurge in literature over the years. In particular, BMPs, Activins, NODAL, and GDFs (referred as 
BANGs) have now shown to participate in tumor development and dissemination (193). 
The most prominent roles of BANGs have been well described during early vertebrate 
development in many studies in mice, fish, and frogs. The earlier role of NODAL in the mouse 
embryo is at the blastocyst state where it is responsible to maintain the pluripotency, such as Oct4 
and Nanog (205). After implantation, a gradient of NODAL helps define the proximal-distal axis to 
establish the anterior-posterior axis of the embryo. In conjunction with BMP and WNT signaling, 
NODAL is essential for mesoderm and endoderm formation and patterning. At later stages, NODAL 
is also required for left-right axis patterning (206, 207). Similarly, the BMPs also act in a gradient in 
early embryos to establish the axis and the tissue patterns along them. BMP-induced patterning is 
molded by its secreted antagonists such as chordin and noggin (208). In later stages of 
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development, both BMPs and GDFs are required for the formation of many different organs such 
as for the regulation of teeth, limb, kidney, skin, muscle, vascular, hematopoietic and neural 
development (209, 210). 
However, a recent surge of papers suggests that many of BANGs roles in cancer is merely 
a redeployment of their roles in early development. Because the central roles of BANGs are to 
regulate stem cell maintenance and expansion, normal tissue hierarchical organization of tissues, 
a disturbance in somatic stem cells may generate cancer stem cells (211), or break down the tissue 
architecture during tumorigenesis. In the colon, two polyposis syndromes are genetically linked to 
aberrant BMP signaling and altered stem cell dynamics. Patients with juvenile polyposis syndrome 
develop hamartomatous polyps in the intestine with an increasing risks of adenocarcinoma. 
Germline mutations in ALK3 or BMPR1A are seen in 20-25% of JPS cases, with additional 15-20% 
of cases having mutations in SMAD4 (212). Hamartomatous polyps are associated with stem cell 
expansion and crypt fission in the colon, reflecting an aberrant BMP-WNT signaling axis. In 
sporadic colorectal cancer, evidence points to the loss of BMP signaling in the transition stage 
between adenoma and carcinoma. About 70% of cases displays inactivating BMP signaling in 
SMAD1, SMAD5, and SMAD8 (213). Cancer stem cells in 20% cases of human glioblastomas are 
rendered unresponsive to anti-proliferative and differentiation-inducing effects of BMPs by silencing 
of the ALK6 promoter (214). In the skin, tumor-educated stroma can override the endogenous BMP 
signaling by secreting antagonists such as Gremlin 1. Gremlin 1 is highly expressed in basal cell 
carcinoma but not in normal skin tissue (215). Additionally, Gremlin 1 overexpression is also 
present in many breast, lung, colon, pancreatic, and esophageal tumors. 
In contrast to BMPs and GDFs, which are both essential for adult tissue homeostasis and 
embryonic development, NODAL is not normally expressed in adult tissues with the exceptions of 
organs that undergo widespread remodeling such as the placenta, endometrium, and lactating 
mammary gland. NODAL expression in adult tissues is predominantly present in pathological 
contexts (216, 217). Pathological NODAL expression was first reported in melanoma, where the 
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amount of NODAL secretion correlated with tumor aggressiveness. Expression of NODAL enables 
melanoma to be less differentiated, more plastic and at the same time, NODAL signaling also 
allows aggressive melanomas to simultaneously express markers of multiple lineages 
(mesenchymal, epithelial, and endothelial). As a result, NODAL overexpression favors functional 
adaptation of melanoma cells to the hostile growth environment (218). Similarly, the phenomenon 
was also extended into prostate, breast and testicular tumors (219-221). In pancreatic cancer, 
NODAL signaling has similar roles as in embryonic development, that is to drive pluripotency and 
self-renewal of cancer stem cells (222). Overexpression of NODAL has been shown in multiple 
human pancreatic cancer cells and enhances metastasis to liver in a splenic xenograft model (223). 
 1.2.4 Tumor-blood vessel interactions during tumor metastasis-cascade 
 Regardless of successful techniques and advances in resecting primary tumors and 
adjuvant therapy to cure confined primary tumors, treatment of metastasis disease from tumor 
dissemination largely remain a clinical challenge to be addressed. Tumor metastasis has 
accounted for >90% of death in cancer patients. Metastasis of carcinomas is a complex and multi-
step process: 1) abnormal tumor cells begin to outgrow and break the basement membrane protein, 
2) tumor cells invade into the stromal environment and interact with stromal cells, 3) tumor cells 
gain access to the blood and lymphatic vessels to intravasate into the circulating blood/lymphatic 
vessels, 4) tumor cells survive rigorous transport in blood stream, 5) tumor cells are arrested at 
distant organ sites and extravasate out of the blood vessels, 6) tumor cells begin to colonize in 
tumor-supporting microenvironment of different distant organs and form secondary tumors (224). 
 One of the hallmarks of tumor growth is angiogenesis. In the early 1970s, Folkman 
postulated that tumors need to be vascularized to grow and that diffusible molecules regulate this 
process. Later, vascular endothelial cell growth factor (VEGF) was identified as one of many 
important factors to recruit blood vessel growth. However, tumor angiogenesis possibly involves 
multiple angiogenic factors besides VEGF as anti-angiogenesis targeting VEGF has been effective 
in some tumors but not others. Interestingly, many tumors develop in highly vascularized tissues, 
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such as brain, liver and lung. In these tissues, tumors can use other mechanism for vascularization 
named vessel cooption (225). Vessel co-option is a mechanism in which tumors obtain a blood 
supply by hijacking the existing vasculature and tumor cells migrate along the vessels of the host 
organ. In a rat glioma model, Holash et al. first observed the process of vessel-cooption, followed 
by vessel regression, tumor hypoxia and the stimulation of angiogenesis for further tumor growth. 
The process of vessel co-option was not just limited to gliomas, but also shown in rat mammary 
adenocarcinoma. In a zebrafish study by Zhao et al (226), vessel co-option and angiogenesis were 
thought to have distinct contributions at the earliest stage of microtumor initiation and metastasis. 
Vessel co-option served an alternative route to obtain nutrient and oxygen during early stage of 
tumor growth. However, angiogenesis played an essential role during the exponential growth during 
tumor progression (227). Interestingly, vessel co-option has also been suggested as a potential 
explanation for failure of anti-angiogenic therapy. 
 It has also been posited that tumor cells may also stay in the wall of blood vessels as they 
break into the blood vessels rather than staying outside the basement membrane in vessel co-
options. Interestingly, Chang et al has shown that GFP-pre-labeled colon carcinoma cells could 
integrate into the blood vessels in both ectopic and orthotopic implantation models to form blood 
vessels with interspersed GFP-labeled tumor cells (228). These mosaic blood vessels were 
accounted for 4% of total vasculature surface. Interestingly, they also demonstrated that mosaic 
vessels are fully functional with perfused fluorescent lectin. These tumor cells were thought to be 
in a transition of intravasating in the blood vessels and stay temporarily in the capillary vessel walls. 
FGF-2 and VEGF-A activated MMP2 activity to increase the mosaic vessels. 
 Interestingly, tumor cells seem to adapt and utilize different mechanisms to vascularize 
their extremely demanding needs for nutrients. In fact, another different concept of tumor self-
vascularized tissue was coined as vascular mimicry. Briefly, vascular mimicry (VM) is described as 
a functional plasticity of aggressive cancer cells to form de novo vascular networks to provide 
perfusion pathway for growing tumors. VM has been reported in multiple cancers including 
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melanoma, glioblastoma, carcinomas, breast, and sarcomas. Historically, vascular mimicry was 
proposed back in 1999 by Maniotis et al. In their study, using an aggressive uveal melanoma, they 
presented that the tumor was lined up with networks of channels interconnected by loops and 
visualized by periodic acid stain (PAS). Interestingly, these PAS positive networks were in close 
contact with the peripheral vascular vessels and partly stained by antibodies against Von 
Willebrand factors, CD34, VEGFR2, and lectin, which are markers for endothelial cells. Thin 
basement membrane was detected using electron microscopy in these networks but endothelial 
cells were not detected. These channels were also perfused with blood cells. Consistently with their 
observations in vivo, very aggressive uveal or cutaneous melanoma cells when cultured in 3D 
Matrigel or collagen matrix also formed architectural loops and network patterns that were 
lumenized and perfused by fluorescent dyes (229).  
 Among tumors, which are capable of VM, cancer cells exhibit a high degree of plasticity 
indicative of a multipotent phenotype similar in many respects to embryonic stem cells (230-232). 
Molecular profiling of these cells displays highly upregulation of genes associated with embryonic 
progenitors (CD133, Nodal), endothelial cells (Notch, VE-cadherin), matrix remodeling (MMP2, 
MMP14), and hypoxia (VEGF, HIF1a, HREs), and down regulation of genes associated with 
lineage-restriction of differentiation. VEGFR1, but not VEGFR2, mediates VEGF-A induced VM in 
melanoma cells and it has been proposed that VM is mediated through synergistic transduction of 
VEGFA/VEGFR1/PI3K/PKCα and integrin signaling pathways (233). Additionally, blocking of Nodal 
signaling has been shown to reduce VM activity of cancer cells (218, 234, 235).  
 1.2.5 Vascular invasion in pancreatic cancer and carcino-endothelialization 
 Although pancreatic cancer is an aggressive and highly metastatic cancer, evidence of 
vascular mimicry has not been described. However, vascular invasion, a process where cancer 
cells break through the blood and lymphatic vessels, is evident in pancreatic cancer. At the time of 
diagnosis, only approximately 16% of patients are present at stage I where the tumor is confined 
within the pancreas while 85%-90% have unresectable tumors (236). Vascular invasion is an 
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important parameter to assess the resectability of pancreatic tumors. Because of the close 
proximity of the pancreas to different large caliber vessels such as the hepatic aorta and veins, 
mesentery aorta and veins, about 21%-64% of patients exhibits vascular invasion according to one 
report (236) at the time of diagnosis. 
 Interestingly, when patient samples from PDAC were examined, microscopy vascular 
invasion was observed in 65.1% of the cases (237). Among the vascular invasion cases, 
histological samples also revealed isolated solitary ductal units (ISDs) within the adipose tissue 
adjacent to the pancreatic tumor. These ISDs were detected mostly in human pancreatic cancer 
patients up to 69.1% in cases with vascular invasion but not in chronic pancreatitis (238). 
Astonishingly, these ISDs exhibited features of vascular structures with evidence of elastin smooth 
muscle layer. However, the endothelial cells with flat morphology were not detected. Instead, the 
ducts are lined with cuboidal epithelial cells that also exhibit intraneoplasia (Figure 1.2). This 
phenomenon of endothelial cell replacement is termed carcino-endothelialization (238). 
 
Figure 1.2. Carcino-endothelialization in the fibroadipose tissue covering the pancreas in patients 
with pancreatic ductal adenocarcinoma. Image was adapted from Bandyopadhyay S. et al. (Am J 
Surg Pathol 2009; 33:425-429). (A) The Elastic-Van Gieson stain to demonstrate the elastin layer 
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around carcino-endothelialization ducts. (B) Smooth muscle actin stain to demonstrate the 
presence of myofibroblastic cells, typically present in vascular wall. 
  
 
CHAPTER 2: ANGIOCHIP, A BIOMIMETIC MODEL TO RECONSTITUTE ANGIOGENIC 
SPROUTING MORPHOGENESIS IN VITRO 
2.1 Abstract 
Angiogenesis is a complex morphogenetic process whereby endothelial cells from existing 
vessels invade as multicellular sprouts to form new vessels.  Here, we have engineered a novel 
organotypic model of angiogenic sprouting and neovessel formation that originates from pre-
formed artificial vessels fully encapsulated within a 3D extracellular matrix. Using this model, we 
screened the effects of angiogenic factors and identified two distinct cocktails that promoted robust 
multicellular endothelial sprouting. The angiogenic sprouts in our system exhibited hallmark 
structural features of in vivo angiogenesis, including directed invasion of leading cells that 
developed filopodia-like protrusions characteristic of tip cells, following stalk cells exhibiting apical-
basal polarity, and lumens and branches connecting back to the parent vessels. Ultimately, sprouts 
bridged between pre-formed channels and formed perfusable neovessels. Using this model, we 
investigated the effects of angiogenic inhibitors on sprouting morphogenesis. Interestingly, the 
ability of VEGFR2 inhibition to antagonize filopodia formation in tip cells was context dependent, 
suggesting a mechanism by which vessels might be able to toggle between VEGF-dependent and 
VEGF-independent modes of angiogenesis. Like VEGF, S1P also appeared to exert its pro-
angiogenic effects by stimulating directional filopodial extension, whereas MMP inhibitors 
prevented sprout extension but had no impact on filopodial formation. Together, these results 
demonstrate an in vitro 3D biomimetic model that reconstitutes the morphogenetic steps of 
angiogenic sprouting, and highlight the potential utility of the model to elucidate the molecular 
mechanisms that coordinate the complex series of events involved in neovascularization. 
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2.2 Introduction 
Angiogenesis, the process by which new capillary vessels sprout from existing vasculature, 
plays a critical role in embryonic development and wound healing, while its dysregulation can 
contribute to cancer progression as well as numerous inflammatory and ischemic diseases (54, 
239) . Consequently, therapeutic strategies to suppress, enhance, or normalize angiogenesis are 
widely sought to treat a broad spectrum of diseases (54, 239) . The most mature amongst these 
approaches targets the activity of angiogenic growth factors, such as vascular endothelial growth 
factor (VEGF), to modulate relevant signaling pathways and control the angiogenesis process. 
Indeed, inhibitors of such pathways have emerged as a mainstay therapy for some cancers and 
diabetic retinopathy (117, 240, 241) . However, it is still unclear how the endothelial cells (ECs) 
lining blood vessels form new vessels, or how angiogenic factors regulate such a dynamic, multi-
cellular process. 
Examining the physical process of angiogenesis requires experimental systems in which 
the formation of new capillary vessels can be easily observed and manipulated. Commonly used 
in vivo models such as the mouse dorsal window chamber, chick chorioallantoic membrane, and 
mouse corneal micropocket assays provide important validation platforms (242, 243) , but are low-
throughput and less suitable for identifying new cell biological mechanisms. In contrast, traditional 
cell culture models of angiogenesis bear little anatomical resemblance to the in vivo process. For 
instance, the tube formation assay involves the reorganization of ECs seeded onto the surface of 
Matrigel into multicellular cords that partially resemble vascular networks but lack important 
features observed in native angiogenesis, such as directional invasion of cells into a 3D 
extracellular matrix (ECM), proper polarization of the luminal and abluminal sides of ECs, lumen 
formation, and support of fluid flow (242, 244) . Assays involving sprouting of ECs from microcarrier 
beads or spheroids capture aspects of multicellular invasion, but the initial geometry of these 
systems requires cells to invade toward their apical domain, counter to the basally-directed invasion 
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in physiologic angiogenesis, and they also lack the continuous fluid flow known to fundamentally 
impact endothelial cell behavior (245).   
In contrast, organotypic models that have faithfully captured biological structure have 
proven to be transformative for a field, as exemplified by studies of engineered skin or mammary 
epithelial morphogenesis (246-248) .  Here, we demonstrate the use of endothelium-lined channels 
as a platform to recapitulate angiogenic sprouting in vitro. The system allowed us to screen 
combinations of angiogenic factors and identify cocktails that induced highly organized, directed 
multicellular sprouting into a surrounding ECM that appears to mimic key morphological aspects of 
in vivo angiogenesis not yet described by other in vitro models. Furthermore, we demonstrate the 
utility of this model by illustrating how pro- and anti-angiogenic agents impact the complex 
multicellular process of angiogenesis. 
 
2.3 Materials and Methods 
Device Fabrication. The device supporting the parallel channels consists of two layers of 
poly(dimethylsiloxane) (PDMS; Sylgard 184; Dow-Corning) bonded to each other and sealed 
against a glass substrate. The top PDMS layer was cast from a PDMS positive mold, previously 
replicated from a silicon wafer template. The bottom PDMS layer was cast off a silicon wafer 
template containing positive features illustrated in supplementary information (Figure 2.S3). 
Dimensions of important features in both layers are shown in Figure 2.1A. To assemble the device, 
the bottom layer was first reversibly sealed to a glass coverslip. The top and bottom layers were 
then separately treated with oxygen plasma, bonded together and cured at 110°C overnight. Upon 
removal from the oven, devices were treated with oxygen plasma to render the exposed PDMS 
surfaces hydrophilic. Hydrophilized devices were immediately treated with 0.1 mg/ml poly-L-lysine 
(Sigma) for 1 hour, followed by 1% glutaraldehyde (Sigma) for 1.5 hours. Devices were washed 
several times with H2O to remove residual glutaraldehyde, sterilized with UV light for 15 min, and 
soaked in 70% ethanol for 1 hour. To mold cylindrical channels, two acupuncture needles (Hwato), 
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400 m in diameter, were inserted into parallel grooves at the top of the bottom layer (Figure 2.S3). 
The needles were passed through the middle rectangular chamber of the device, resting 
approximately 200m above the glass coverslip surface. Rat tail collagen I, at 2.5 mg/ml, was 
pipetted into the middle chamber and allowed to polymerize at 37oC for 30 minutes. Excess 
collagen was subsequently aspirated from the fluid reservoirs feeding from the middle chamber. 
Devices were then covered with EGM-2 (Lonza) for at least 4 hours before the needles were 
extracted as previously described . Devices were then covered in EGM-2 for at least two days prior 
to seeding with cells.  
Cell Culture and Seeding in Devices. Human umbilical vein endothelial cells (HUVECs) 
(Lonza) were cultured in EGM-2. HUVECs, from passage seven to nine, were used in all 
experiments. HUVECs were concentrated at 107cells/mL and seeded into one of the two channels. 
The device was inverted to allow HUVECs to adhere to the top surface of the channel for 10 
minutes, and then flipped upright to allow cells to adhere to the bottom surface of the channel for 
another 10 minutes.  Cells that adhered in the fluid reservoirs were scraped off with a pipette tip, 
and unattached cells in the channel were thoroughly flushed out with phosphate-buffered saline 
(PBS). EGM-2 was immediately added thereafter and the devices were placed on a platform rocker 
(BenchRocker, BR2000), oscillating at 0.1Hz and with a maximum tilt of 9.5o in order to generate 
gravity-driven flow across the channels. Cells were cultured in channels for 1-2 days before the 
experiment was initiated. 
Immunofluorescence Staining. At designated time points, cells in the devices were fixed 
in situ with 3.7% formaldehyde for 45 minutes. For CD31 immunohistochemistry staining, cells were 
permeabilized with 0.1% Triton-X for 30 minutes, blocked in 3% BSA overnight at 4oC, washed 3 
times with PBS and incubated with mouse monoclonal antibody against human CD31 (1:200, 
Dako). For Laminin and Podocalyxin immunohistochemistry staining, the cells were blocked with 
3% BSA overnight at 4oC, washed 3 times with PBS and incubated with either rabbit polyclonal 
antibody against Laminin (1:100, Chemicon) or goat polyclonal anti-human podocalyxin (1:100, 
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R&D) overnight at 4oC. Before secondary antibody incubation, the devices were washed overnight 
with PBS at 4oC. All secondary antibodies (Invitrogen) were used at 1:500 dilution. In addition, cell 
nuclei were stained with DAPI (1:500, Sigma) and F-actin was stained with Alexa Fluor 488-
conjugated Phalloidin (1:100, Sigma). Before imaging, all devices were completely submerged in 
PBS for 2-3 days to remove background staining.   
Image Acquisition and Processing. Brightfield images of sprouts were acquired with a 
Nikon TE200 epifluorescence microscope (Nikon Instruments, Inc.) using 10x. Confocal 
immunofluorescence images were acquired with either 10x air objective or LD C-Apochromat 40x, 
1.1 numerical aperture (N.A.) water immersion objective attached to either an Axiovert 200M 
inverted microscope (Zeiss) equipped with an CSU10 spinning disk confocal scan head (Yokogawa 
Electric Corporation), and an Evolve EMCCD camera (Photometrics) or an Olympus IX 81 
microscope (Olympus America, Inc.) equipped with an CSU-X1 spinning disk confocal scan head 
(Yokogawa Electric Corporation), and an Andor iXon3 897 EMCCD camera (Andor Technology). 
ImageJ was used to merge channels, perform Z-projection for all confocal stacks, and generate 
longitudinal and transverse cross-sections. Custom MATLAB scripts and ImageJ were used to 
stitch images together. 
Screening of Angiogenic Factors. In screening experiments, the endothelialized ‘parent’ 
vessel was perfused with EGM-2 while the adjacent source channel was perfused with EGM-2 
enriched with angiogenic factors. Angiogenic factors include Vascular Endothelial Growth Factor 
(VEGF), Monocyte Chemotactic Protein-1 (MCP-1), Hepatocyte Growth Factor (HGF), and basic 
Fibroblast Growth Factor (bFGF), all purchased from R&D Systems. Sphingosine-1-Phosphate 
(S1P) and Phorbol Myristate Acetate (PMA) were purchased from Cayman Chemical and Sigma, 
respectively. VEGF, MCP-1, bFGF, HGF, and PMA were all used at 75ng/mL while S1P was used 
at 500nM. EGM-2 and enriched EGM-2 were refreshed daily for up to six days. Brightfield images 
were acquired daily for quantification. 
Bead Perfusion of Microvessels. After neovessels bridged the two preformed channels 
in the device, a solution of CellTracker CM-DiI (Invitrogen) was delivered into the parent vessel to 
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stain live HUVECs and neovessels in situ. Fluorescent beads (Polysciences) of 3 μm diameter 
were suspended in PBS and perfused into the parent vessel at a flow rate of 5 µL/min. Images of 
flowing beads were acquired at 40 frames/sec using an Eclipse TE2000 inverted epifluorescence 
microscope equipped with a live cell incubator and an Evolve EMCCD camera. Frames of bead 
time-lapse movie were stacked and overlaid with image of DiI-stained neovessels using custom 
Matlab code. Bead-video samples were subsequently fixed and imaged with a 10x air objective 
attached to a Leica LSM 710 confocal microscope system. 
Inhibition of Angiogenic Sprouting. The effects of inhibitors targeting VEGFR2 
(Semaxanib, Cayman Chemical), S1P receptors (Fingolimod, Selleck Chemicals) and MMPs 
(Marimastat, Tocris Bioscience) were evaluated in a similar setup to the angiogenic factor 
screening experiments. HUVECs were cultured in the ’parent’ vessel in either full EGM-2 (for 
Marimastat experiments) or incomplete EGM-2 lacking VEGF and bFGF (for Semaxanib and 
Fingolimod experiments). In all cases, the angiogenic source channel contained the same media 
as the ‘parent’ vessel supplemented with either the MVPS or HFMVS cocktails described in 
Results. In separate devices, Semaxanib or Fingolimod were administered into both channels at 
14 µM and 140 nM to yield effective concentrations of 10 µM and 100 nM, respectively, due to the 
additional volume of the gel. Marimastat was administered only into the source channel at 0.6 μM. 
All inhibitors were added daily at starting on concurrent with or three days after the initial addition 
of angiogenic cocktails. Media in both channels were refreshed daily.  Brightfield images were 
acquired daily for quantification. 
Quantification of Sprout Length and Sprout Density. Custom MATLAB code was 
written to measure the individual distances from the leading protrusions of tip cells to the wall of 
the parent vessel. Tip cells were additionally quantified as either attached to stalk cells extending 
from the endothelialized channel or as isolated single cells (Figure 2S1). Sprouting metrics were 
quantified for the screening experiment (n = 2 samples per condition), the VEGFR2 and S1P 
inhibitor experiment (n = 5 samples per condition), and the MMPs inhibitor experiment (n = 3 
samples per condition). 
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Filopodia Quantification and Analysis. Projections from z-resolved confocal stacks, 
which were taken using 25x water immersion objective attached to Axiovert 200M inverted 
microscope (Zeiss) with spinning disk confocal scan head, were used to analyze filopodia length 
and number. A custom MATLAB code was used to determine the distance from the tips of filopodia 
to the center of cell nuclei and count the number of filopodia. The number and length of filopodia 
were averaged over the number of cells across 3 samples per condition. 
Statistical Analysis. Sample populations were compared using unpaired, two-tailed 
Student’s t-test. P < 0.05 was the threshold for statistical significance. Data points on the graphs 
represent mean values and error bars depict SEM. 
 
2.4 Results 
A microengineered platform that supports angiogenic sprouting and neovessel 
formation in vitro 
To study the process of angiogenic invasion and sprouting from an existing vessel, we 
designed a device in which an endothelium lining a cylindrical channel was fully surrounded by 
matrix and exposed to a gradient of angiogenic factors emanating from a parallel source channel 
(Figure 2.1A). The device was assembled by casting Type I collagen into a PDMS mold/gasket with 
two parallel needles held across the casting chamber. Upon collagen polymerization, the needles 
were extracted to create hollow cylindrical channels in the collagen matrix (Figure 2.1A). 
Endothelial cells (ECs) were then injected into one of the channels, allowing them to attach on the 
interior wall and form a confluent endothelium or “parent vessel” (Figure 2.1B). Flow was 
maintained through both channels for the duration of the experiments and media containing 
angiogenic factors was subsequently added to the second channel to establish a gradient across 
the collagen matrix to the endothelium (Figure 2.1B). Thus, the device design provided a means to 
promote and visualize endothelial sprouting that might emulate early angiogenic processes. 
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Using this device, we first examined how various pro-angiogenic factors might impact 
directed invasion and sprouting from the parent vessel. Six common factors associated with 
angiogenesis in the literature were selected: basic fibroblast growth factor (bFGF) (249) , 
hepatocyte growth factor (HGF) (250) , vascular endothelial growth factor (VEGF) (58, 251), 
monocyte chemotactic protein-1 (MCP-1) (85), sphingosine-1-phosphate (S1P) (252), and Phorbol 
12-myristate 13-acetate (PMA) (253). After these factors were added individually to the non-
endothelialized source channel, phase-contrast and confocal microscopy were used to assess the 
organization and development of EC invasion over four days. We found that VEGF, MCP-1, HGF 
or bFGF alone did not induce significant invasion into the matrix, while S1P and PMA resulted in 
substantial directed invasion (Figure 2.S1). This invasion was oriented directly toward the source 
channel, despite the fact that cell migration from the endothelium was not artificially constrained in 
any direction by our system design (Figure 2.1C).  
Interestingly, S1P and PMA stimulated markedly different modes of cell migration. S1P 
drove chemotactic migration primarily of single cells from the endothelialized channel, whereas 
PMA triggered collective cell migration that manifested itself in the form of sparse, long, multi-
cellular sprouts into the matrix (Figure 2.1Ci,ii). Progressively more complex combinations of the 
six factors yielded more substantial multicellular sprout-like structures, especially in the case of two 
distinct combinations that drove robust sprouting – HGF, bFGF, MCP-1, VEGF, and S1P (HFMVS) 
and MCP-1, VEGF, PMA, and S1P (MVPS) (Figure 2.S1). HFMVS-guided invasion exhibited 
numerous sprout-like structures that extended hundreds of micrometers from the endothelialized 
parent vessel as well as large numbers of solitary cells migrating into the matrix (Figure 2.1C iii,iv). 
The MVPS cocktail induced an even greater multicellular sprouting response with less single cell 
migration (Figure 2.1Cv). In both cases, the sprouts continued to invade toward the source channel 
as long as the gradient was maintained. 
Remarkably, when the tips of these sprouts reached the source channel (typically after one 
week), they breached into the source channel, forming what appeared to be new microvessels 
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connecting the two parallel channels (Figure 2.1D). To test whether these “neovessels” possessed 
functional, perfusable lumens, 3µm fluorescent beads were added to the media flowing into the 
endothelialized parent channel. Beads traveled through the neovessels to the source channel with 
no leakage into the interstitial space, indicating fully developed lumens lined by a continuous 
endothelium. Overlaying frames of the time-lapse images demonstrated the path of the beads 
through these occasionally branching neovessels (Figure 2.1D).   
 
 
 
Figure 2.1. 3D formation of endothelial sprouts and neovessels in a microfluidic device. (A) Device 
schematic. Parallel cylindrical channels are encased in 3D collagen matrix within a microfabricated 
PDMS gasket and connected to fluid reservoirs. One channel is coated with ECs and perfused with 
medium while the other channel is perfused with medium enriched with angiogenic factors. (B) 
Photograph of the device.  Zoom shows phase (top) and fluorescent (bottom) micrographs of an 
endothelialized channel. F-actin and nuclei are labeled with phalloidin (green) and DAPI (blue), 
respectively.  (C) Representative confocal immunofluorescence images of sprouting and migrating 
ECs in response to gradients of different pro-angiogenic factors: S (i), P (ii), HFMVS cocktail (iv), 
and MVPS cocktail (v). Panel iii shows a phase image of directed sprouting induced by HFMVS. F-
actin and nuclei are labeled with phalloidin (green) and DAPI (blue), respectively. (D) Neovessels 
in the device are shown in (i) a merged image of a time-lapse movie tracking the position of 3m 
red fluorescent beads perfused through the large channels and neovessels and (ii) a z-projection 
confocal image of the same vessels. Beads were added to the left end of the parent vessel and 
flowed through neovessels to the factor source channel. In both images ECs (green) are labeled 
with DiI. Scale bars of 2x zoom-in insets in (C) are 50 m.  All other scale bars are 100 m. 
Abbreviations: F=bFGF, H=HGF, M=MCP-1, P=PMA, S=S1P, V=VEGF. 
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Sprouts exhibit morphologic features of in vivo angiogenesis 
Because this experimental model allows us to monitor the detailed structural events of 
sprouting, we next proceeded to examine the changes in cellular organization during early stages 
of invasion. For this purpose, we focused on the MVPS cocktail, which promoted the greatest 
sprouting response with minimal single cell migration. Prior to stimulation, cells in the 
endothelialized channel exhibited the expected apical-basal polarity as demonstrated by the 
localization of CD34 apical marker podocalyxin to the luminal face (254). On the basolateral side 
of the endothelium we observed laminin deposition. Upon stimulation, occasional single ECs began 
invading into the matrix and extending filopodia-like protrusions in the direction of the angiogenic 
gradient (Figure 2.2A). During initial invasion, we observed interruptions in laminin 
immunofluorescence, consistent with focal degradation of the basement membrane (Figure 2.2B). 
These leading tip cells were replete with filopodia-like protrusions, morphologically recapitulating 
in vivo sprout tips (50). As these tip cells migrated deeper into the matrix, neighboring cells followed 
while maintaining cell-cell contacts along the length of the sprout, as shown by PECAM-1  staining 
(Figure 2.2C). Thus, the sprouting process from the parent endothelium into the matrix involved 
collective cell migration that supported a contiguous structure between the sprout and parent 
vessel. Even at this early stage of 2-3 cells per sprout, evidence of lumen formation was detected 
in 3D reconstructions of confocal images (Figure 2.2D). Moreover, apical-basal polarity appeared 
intact in the sprouts as evidenced by apically targeted podocalyxin staining (Figure 2.2Di,iii).  
As the sprouts continued to invade and extend into the matrix, they became longer, 
contained progressively more cells, and began to branch (Figure 2.2E-G). Stereotypical sprouting 
morphology was evident in these mature sprouts, with cells at the sprout tip developing numerous 
thin filopodia-like protrusions, in contrast to cells in the stalk containing few filopodia protrusions 
(Figure 2.2E-G). Lumens developed in both early and late sprouts that often extended from the 
parent vessel up to, but never within, the tip cell (Figure 2.2D,E). Partial lumens occasionally were 
evident behind the tip cell that were not connected to the parent vessel, suggestive of spontaneous, 
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focal cord-hollowing or lumenization (Figure 2.2Fiv). Staining confirmed that the sprout tip cells 
lacked specific localization of podocalyxin, while stalk cells demonstrated localization of 
podocalyxin to the luminal space (Figure 2.2E). We observed laminin deposition in the mature 
sprouts (Figure 2.2F) and found that PECAM-1-positive cell-cell junctions were generally intact 
throughout the sprouts (Figure 2.2G). In addition to primary sprouts, maturation of secondary 
branches also occurred in our system. Different stages of secondary branching were evidenced by 
stalk cells occasionally marked by direct filopodia-like protrusions suggesting early branch initiation 
(Blue arrow, Figure 2.2F), whole cells extending out from the stalk of the sprout (Blue arrow, Figure 
2.2E), and finally as full multicellular branches with their own new tip cells extending toward the 
angiogenic gradient (Figure 2.2G).   
Upon formation of neovessels spanning the two channels, non-perfused filopodial 
protrusions notably disappeared (Figure 2.2Hi). The neovessels were lumenized end-to-end 
(Figure 2.2Hii, iii), and cells were aligned with flow as in the parent vessel, demonstrated by actin 
stress fiber alignment (Figure 2.2Hiv). Further examination revealed the deposition of laminin 
around the neovessels (Figure 2.2I), localization of podocalyxin to the luminal domains (Figure 
2.2J), and PECAM-1 staining reflective of intact cell-cell junctions (Figure 2.2K). 
 
Figure 2.2 Characterization of early and late sprouts and neovessels. Representative confocal 
immunofluorescence images of early (A-D) and late (E-G) sprouts and neovessels (H-K). For all 
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images F-actin and nuclei are labeled with phalloidin (green) and DAPI (blue), respectively. Staining 
for laminin (B, F, I), PECAM-1 (C, G, K), and podocalyxin (podclxn; D, E, and J) are shown in red. 
(A) Micrograph of an EC extending processes into the matrix towards the source channel. (B) 
Laminin immunofluorescence (red) is marked by white arrowheads on the abluminal side of the 
parent vessel. Fluorescence is interrupted by early sprout invasion. (C) Image of an early 
multicellular sprout stained for F-actin (green) and PECAM-1 (red). White arrowheads point to 
PECAM-1 staining at cell-cell junctions. Inset: z-projection of back half of sprout showing only red 
channel (PECAM-1). (D) Early sprout stained for podocalyxin (red) shown in z-projection (i), and 
single slice (ii, iii). White arrowheads mark podocalyxin at luminal side of sprout shown by 
transverse (inset, i) and in-plane (ii) sections. (E) Mature sprout stained for podocalyxin (red) shown 
in z-projection (i) with blue arrow marking cell invading out from sprout stalk, and in cross-sections 
of tip cell (ii) showing no lumen or spatial podocalyxin localization in the cell, and stalk (iii) with 
white arrowheads marking podocalyxin staining at apical side of lumenized stalk cells.  (F) Mature 
sprout stained for laminin (red) shown in z-projection (i) with blue arrow marking stalk cell filopodia, 
and in cross-sections of sprout tip cell (ii) that contains no lumen and shows presence of laminin 
staining, in lumen-containing stalk cell (iii) with white arrowheads marking laminin staining at basal 
side, and stalk cell that contains no lumen (iv) showing laminin immunofluorescence. (G) Mature 
sprout stained for PECAM-1 (red) shown in full z-projection (i) and z-projection of back half of sprout 
(ii). White arrowheads in (ii) mark PECAM-1 staining at cell junctions. (H) Neovessel shown in z-
projection (i), cross-section (ii), and in-plane slice (iii). F-actin (iv) shows actin fiber alignment with 
direction of flow indicated by double-arrow line. (I) Neovessel exhibits laminin staining (red) at its 
basal side (white arrowheads). (J) Neovessel exhibits podocalyxin staining (red) at its luminal side 
(white arrowheads). (K) Neovessels express PECAM-1 staining (red) at cell junctions (white 
arrowheads). Yellow, pink, orange boxes indicate longitudinal slice or partial stack, transverse 
cross-section, and zoom-in, respectively. Scale bars are 25 m. 
VEGF drives directed filopodia formation and sprout extension in a context 
dependent manner 
While the structural similarities between angiogenic sprouts observed in our system and 
those found in vivo were broadly encouraging, it was also important to explore whether our 
angiogenic sprouts responded physiologically to agents known to perturb the angiogenic process. 
To address this question, we investigated whether anti-angiogenic agents could impact sprouting 
in our system. First, a VEGF receptor 2 (VEGFR2) inhibitor Semaxanib (255, 256)  was added with 
the HFMVS angiogenic cocktail. If added from the outset, the inhibitor abrogated sprout initiation 
(Figure 2.3A). Because angiogenic inhibitors are also thought to lead to regression of pre-existing 
sprouts (257), we also tested the effects of adding Semaxanib to the source channel after 3 days 
of uninhibited sprouting. We found that further progression of sprouts was arrested, but obvious 
regression of the sprouts did not occur (Figure 2.3A). Closer inspection of VEGFR2-inhibited sprout 
architectures revealed a near complete loss of the many filopodia-like protrusions normally present 
in the tip cells, with a decrease in the number and length of protrusions (Figure 2.3B,C). 
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Surprisingly, we observed that sprouting induced by the MVPS cocktail, while slowed, appeared to 
proceed despite VEGFR2 inhibition (Figure 2.3D). Confocal images revealed that the filopodia-like 
protrusions in these sprouts were largely unaffected by Semaxanib, whether added at Day 0 or Day 
3 (Figure 2.3F). Quantitative analysis showed that the number of filopodial extensions was 
unchanged and their length was unaffected (Figure 2.3E). Importantly, these results demonstrate 
that the angiogenic process modeled by our system can respond to physiologically relevant anti-
angiogenic therapeutics. Moreover, this system offers insights into the mechanism by which 
Semaxanib may antagonize angiogenesis, by arresting the formation of cellular protrusions that 
are critical to the initiation and growth of angiogenic sprouts. Interestingly, in contexts containing 
factors that can promote protrusive activity in a VEGF-independent manner, angiogenic sprouts 
become refractory to Semaxanib. 
 
Figure 2.3. Effects of VEGFR2 inhibition on angiogenic sprouting. (A, D) Plot of sprout length driven 
by HFMVS (A) or MVPS (D) in response to Semaxanib treatment over time. Pro-angiogenic cocktail 
was initiated at Day 0 and Semaxanib treatment was initiated at either Day 0 (Day 0 Sem), Day 3 
(Day 3 Sem), or never (No Inhib). (B,E) Quantification of filopodia length and number in sprouting 
for inhibitor treatment versus no-inhibitor control. (C,F) Representative confocal 
immunofluorescence images of indicated conditions at Day 6. F-actin and nuclei are labeled with 
phalloidin (green) and DAPI (blue), respectively. Grid indicates no detectable signal so no data was 
acquired. Scale bars are 50 m.  Error bars are SEM. * represents significant difference from control 
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(p < 0.05). ns represents no significant difference from control. N = 5 samples for sprout length 
quantification, N = 3 samples for filopodia quantification. All filopodia quantifications performed on 
data from Day 6 of experiment.  
 
S1P and MMP inhibition demonstrate independent steps for angiogenic invasion  
To further investigate the morphogenetic responses to anti-angiogenic factors, we 
examined the effects of perturbing S1P signaling, which acts as a strong chemoattractant through 
a G-protein coupled receptor (S1PR) and is known to regulate angiogenesis (258, 259). Exposing 
cells to the S1PR inhibitor Fingolimod (260) resulted in abrogation of sprout initiation when 
introduced at Day 0, and inhibited further sprout extension when given at Day 3 (Figure 2.4). 
Interestingly, these effects were independent of which angiogenic cocktail (HFMVS or MVPS) was 
employed (Figure 2.4A,D). Quantification of the remaining sprout structures revealed nearly 
complete loss of filopodia-like protrusions, with cells appearing less elongated and organized 
(Figure 2.4B,C,E,F). These data suggest that S1P signaling also regulates angiogenic sprouting, 
and that multiple pathways in addition to VEGF signaling may contribute specifically to the 
directional protrusions necessary for sprout extension. However, though necessary, we would 
anticipate that filopodial protrusions are only one of several key cellular processes required for 
sprout extension. In support of this, we observed that the broad spectrum MMP-inhibitor, 
Marimastat (261, 262), also blocked sprout invasion and extension (Figure 2.S2), but had no effect 
on directed filopodial extension. 
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Figure 2.4. Effects of S1P receptor inhibition on angiogenic sprouting. (A, D) Plot of sprout length 
driven by HFMVS (A) or MVPS (D) in response to Fingolimod treatment over time. Pro-angiogenic 
cocktail was initiated at Day 0 and Fingolimod treatment was initiated at either Day 0 (Day 0 Fing), 
Day 3 (Day 3 Fing), or never (No Inhib). (B,E) Quantification of filopodia length and number in 
sprouting for inhibitor treatment versus no-inhibitor control. (C,F) Representative confocal 
immunofluorescence images of indicated conditions at Day 6. F-actin and nuclei are labeled with 
phalloidin (green) and DAPI (blue), respectively. Grid indicates no detectable signal so no data was 
acquired. Scale bars are 50 m.  Error bars are SEM. * represents significant difference from control 
(p < 0.05). ns represents no significant difference from control. N = 5 samples for sprout length 
quantification, N = 3 samples for filopodia quantification. All filopodia quantifications performed on 
data from Day 6 of experiment. 
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Figure 2.S1. Characterization of gradient between parent vessel and source channel. Relative 
intensity profile at 2, 5, and 60 min after addition of 20kDa fluorescently tagged dextran. A 1D 
solution to Fick’s Law using data acquired at 2 min after introduction of the dextran provided an 
estimate for the diffusion coefficient of 1.80 x 10-6 cm2/s 
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Figure 2.S2. Quantitative metrics for scoring number and length of sprouts and single cell 
migration. (A) Leading cells are categorized as sprout tip cells (black arrowheads) when in contact 
with stalk cells connected to the parent vessel (dashed white line), or as isolated, single cells (white 
arrowheads). Sprout length was measured as the distance between leading protrusions of sprout 
tip cells and the nearest point along the parent vessel. Scale bars are 100 m. (B) Plot of sprout 
length and the number of sprout tip cells and single cells after 4 days of exposure to indicated 
factor(s). N = 2 samples per condition. (C) Representative phase images of each condition after 4 
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days of exposure to indicated factor(s). Scale bars are 200 m. Abbreviations: F=bFGF, H=HGF, 
M=MCP-1, P=PMA, S=S1P, V=VEGF. 
 
Figure 2.S3. Characterization of cell-deposited extracellular matrices by the endothelium. (A) 
Laminin immunofluorescence (red) is shown in a z-resolved confocal stack en face projection of a 
parent vessel (i), with zoomed-in view (ii). Radial slice (iii) indicating localization of laminin at the 
basal side. (B) Collagen IV immunofluorescence (red) is shown in a z-resolved confocal stack 
projection of a parent vessel (i), with zoomed-in view (ii). Radial slice (iii) indicating localization of 
collagen IV at the basal side. F-actin and nuclei are labeled with phalloidin (green) and DAPI (blue). 
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Figure 2.S4. Quantification of sprout length for the MVPS and MPS cocktails at day 4. MVPS and 
MPS cocktails were only added to the source channel. Error bars are SEM. Ns, no significant 
difference from MVPS control (P≥0.05). 
 
 
Figure 2.S5. Quantification of sprout length for different S1P gradients. (A) Plot of sprout length at 
day 4 for the MVPS cocktail in source channel (control gradient), MVPS in source channel plus 
S1P in parent vessel (no gradient), MVP in source channel plus S1P in parent channel (negative 
gradient), and MVP in source channel (no S1P). (B) Plot of sprout length at day 4 for the MVPS 
cocktail in source channel with different concentrations of S1P: 250nM (low gradient), 500nM 
(control gradient), and 1µM (high gradient). * Significant difference from the MVPS (control 
gradient) (P≥0.05); ns, no significant difference from MVPS (control gradient) control. 
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Figure. 2.S6. Effects of MMP inhibition on angiogenic sprouting. (A) Plot of sprout length driven by 
MVPS in response to Marimastat treatment over time. Pro-angiogenic cocktail was initiated at Day 
0 and Marimastat treatment was initiated at either Day 0 (Day 0 Mar), Day 3 (Day 3 Mar), or never 
(No Inhib). (B) Representative confocal immunofluorescence images of indicated conditions at Day 
6. F-actin and nuclei are labeled with phalloidin (green) and DAPI (blue), respectively. Scale bars 
are 50 m.  Error bars are SEM. * represents significant difference from control (p < 0.05). N = 3 
samples for sprout length quantification.  
 
 
Figure 2.S7. Schematic of the device manufacturing process. A silicon template (blue and white) 
containing four rectangular features for the top layer of the device was made using UV lithography 
(I). Uncured PDMS (beige) was cast onto silicon template (II). After curing at 80 C, PDMS top layer 
(beige) was cast off the template (III). A silicon template containing four linked rectangular features 
was used to make a bottom positive PDMS mold (grey) (IV). Uncured PDMS (green) was cast onto 
positive PDMS mold and a glass slide was applied to trap the PDMS between the mold and glass 
(V). System was inverted (VI). After curing at 110 C, PDMS bottom layer (green) was cast off the 
PDMS mold and adhered to a glass coverslip (VII). Following oxygen plasma treatment, top and 
bottom PDMS layers were aligned and sealed and placed in a 110 C oven overnight. 
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2.5 Discussion 
Although central to angiogenesis, the morphogenetic process of endothelial invasion and 
sprout extension has been difficult to observe in vivo and models of sprouting in vitro have largely 
ignored the key initial conditions in which sprouts emanate from ECs lining a perfused vessel. 
Several tissue engineering approaches have been developed recently in which endothelial cells 
can be seeded into a channel within extracellular matrix to form a primitive vasculature (263-265). 
Here, we built on this concept with a device that allows angiogenic factors to trigger directed 
invasion and sprouting from such vessels, and used it to examine sprouting events. Other designs 
have been presented for studying sprouting that use channels with square rather than circular 
cross-sections in which endothelium lines a planar sidewall of matrix and expose cells to contact 
with silicone or glass on top and bottom walls (135, 266, 267). Although the close proximity of cells 
to the glass and silicone walls likely prevents cells from forming fully developed sprouts, the 
simplicity of such devices are an attractive alternative for more focused modeling of cellular 
invasion. In contrast, the system presented here allows cells to emanate outwards from the vessel 
wall in all directions without introducing such physical constraints, and thus provides a new avenue 
for studying multicellular, morphogenetic aspects of angiogenesis.  
The ability to assess the organization of invading cells was a critical feature that enabled 
us to begin to characterize and isolate factors that support the many steps involved in angiogenic 
sprouting. In our system, VEGF alone had negligible effect on sprouting while S1P only triggered 
single cell migration. Instead, only in the presence of a more complex cocktail of multiple factors 
could we observe robust multicellular sprout-like invasion where a morphologically distinct leading 
tip cell was trailed by a multicellular stalk. Interestingly, our results suggest that different 
combinations of factors can be similarly potent. In line with these findings, one recent study reported 
that a combination of factors secreted by stromal fibroblasts was necessary to induce sprouting 
(268). Another study suggested that exposure to a combination of hematopoietic chemokines, 
VEGF, and FGF led to a marked enhancement in tubulogenesis and sprouting (269). The 
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recognition that multiple combinations of factors can drive angiogenesis, likely through different 
mechanisms, further underscores an important role for model systems that allow for the rapid 
characterization of factor combinations.  
With the appropriate stimuli in place, sprout formation and extension in our system 
proceeded through a well-defined progression that mirrored major steps of in vivo angiogenesis, 
including directed tip cell invasion, multicellular stalk formation, lumen formation, and neovessel 
perfusion. These steps are consistent with seminal observations of in vivo angiogenesis showing 
the emergence of tip cells from an existing vessel, and stalk cells that establish apical/basal polarity 
and form a lumen that excludes the tip cell (50, 254, 270). VEGF has been shown to be important 
in triggering such tip cells to extend thin, actin-rich protrusions and in guiding stalk cells to form 
elongated multi-cellular sprouts (50, 117). Here, we showed that both VEGF and S1P signaling 
appear to drive these filopodia-like protrusions and sprouting, consistent with mechanistic studies 
suggesting that multiple angiogenic factors can activate Cdc42, a key GTPase for filopodia 
formation. Interestingly, the effect of VEGFR2 inhibition on sprouting depended on the composition 
of the angiogenic cocktail, and may explain why some anti-VEGF inhibitors block angiogenesis in 
some instances but not others.  
Many distinct mechanisms have been described for in vivo lumen formation (271). In our 
system, we observed fully developed lumens formed by stalk cells lining a tunnel left behind the 
leading tip cell. In other instances, the lumen was present only just behind the tip cell, not yet 
extending contiguously back to the base of the stalk, suggesting spontaneous lumen formation by 
the stalk cells. These observations are consistent with mechanisms for lumenization observed in 
vivo. Finally, in addition to the simple coordination of tip and stalk cells to form linear vessels, our 
system also seems to support higher-order events such as branching, a key mechanism to the 
patterning of sprouts controlled by the dynamic interconversion of stalk cells and filopodia-
containing tip cells (50, 272-275), as well as loss of filopodial activity and regression upon eventual 
perfusion of the neovessel, a critical component of microvascular pruning and remodeling (276). 
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The basis for this type of pruning could be explained by recent studies reporting that shear stress 
could suppress VEGF-induced invasion (266). Thus, the system introduced here faithfully 
recapitulates key features of in vivo angiogenesis and provides the ability to link specific stimuli to 
defined morphogenetic processes, further illustrating the power of such a model. 
Loss-of-function in vivo models remain the mainstay for studying both physiologic and 
pathologic processes, including those involving angiogenesis (242, 277). However, organotypic 
models that are able to capture basic features of these processes in an in vitro setting undeniably 
offer additional levels of control and analysis that are critical to gaining mechanistic insights (248). 
The model system presented here highlights that the field of angiogenesis has matured sufficiently 
to enable reconstitution of the complex morphogenetic changes within endothelial cells as they 
invade to form multicellular sprouts and newly perfused vessels. Even so, it represents merely a 
first step toward establishing a new platform for investigating vascular remodeling. Indeed, the 
introduction of additional cell types, including stromal, parenchymal, and circulatory cells, could 
open the door to establishing a deeper understanding of how different microenvironmental, genetic, 
organ-specific, and pathologic factors could contribute to the different forms of angiogenesis. This 
study adds to recent developments (278, 279) that together highlight the importance of engineered 
experimental models as a new approach to studying biological processes. 
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CHAPETER 3: THE ROLE OF CDC42 IN BRANCHING MORPHOGENESIS 
3.1 Abstract 
 Angiogenesis is a highly dynamic process where endothelial cells extensively rearrange 
their cytoskeletal structures to migrate and coordinate between tip and stalk cells in a collective 
manner. The Rho family of GTPases has been shown to be important regulators of cytoskeletal 
rearrangement during cell migration. However, the roles of Rho GTPases in angiogenesis remains 
unclear. Particularly, conditional knockout of Cdc42 in endothelial cells resulted in lethality in mouse 
embryos and defects in formation of vasculature, which makes it challenging to understand the 
roles of Cdc42 in the morphogenetic processes of angiogenesis. In vitro manipulations of Cdc42 
indicated the role of Cdc42 in lumen formation in 3D tubulogenesis. But its role in other 
morphogenetic processes of angiogenesis such as formation of branching is largely unknown. 
Here, using a previously developed 3D biomimetic model of angiogenesis, we examine the roles 
of Cdc42 in branching morphogenesis of angiogenic sprouting. We find that inhibition of Cdc42 
though reduces migration speed has minimal effect on directional migration of 3D sprouting. 
Disturbance of Cdc42 activity leads to less branching in angiogenesis but has no effect on the 
length of branches. We also observe the role of Cdc42 to regulate collective migration. Interestingly, 
we also find that Cdc42 negatively regulates filopodia formation. Taken all together, our study 
reveals the many aspects of Cdc42 to mediate different morphogenetic processes of angiogenic 
sprouting. 
 
3.2 Introduction 
Angiogenesis is a process where new blood vessels form from existing vasculature. During 
endothelial cell sprouting, endothelial cells from the blood vessels detect and respond to angiogenic 
cues. The endothelial cells then probe the environment using their filopodia protrusions, and digest 
the vascular basement membrane to extend their bodies into the interstitial tissue to form tip cells 
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with following stalk cells (50). Tip cells and stalk cells form multicellular sprouts, which ultimately 
develop into mature perfusable blood vessels with hierarchical structures (168). To establish these 
ordered vessel networks, sprouts have to extensively form multiple branching structures and 
undergo changes such as pruning to remodel the structures. Such processes require dynamic 
changes in cytoskeleton of endothelial cells.  
Rho GTPase proteins are known to regulate actin cytoskeleton dynamics in cell migration 
during organ development and tissue morphogenesis (138). Among Rho GTPase proteins, Cdc42 
has a conserved role to regulate cellular polarity, cell cycle division and actin cytoskeleton 
dynamics. More importantly, Cdc42 has been shown to regulate the formation of filopodia in 
different cell types including fibroblasts, immune cells, and endothelial cells in 2D culture (138). In 
neuronal cells, deletion of Cdc42 led to reduction in branching of growth cones (158, 159, 280). In 
vivo deletion of Cdc42 whether global or endothelial-cell-specific knockout, has resulted in similar 
defects in vascular formation in both fetal and adult vasculatures. More specifically, formation of 
the vascular tree lack branching structures in the trunk and heart of mice with genetic knockout of 
Cdc42 (170). However, as both vasculogenesis and angiogenesis concomitantly occur during 
embryonic development to form the branching network of the vasculature, it is a challenge to 
decipher the role of Cdc42 in the morphogenetic processes of angiogenesis.  
Despite the implication of Cdc42 in mediating branching morphogenesis in angiogenesis, traditional 
culture of endothelial cells on Matrigel has attempted to answer the formation of branching network 
but the assay does not fully capture the 3D microenvironment where angiogenesis typically occurs 
within eukaryotic organs (242). Additionally, studies of Cdc42 in 3D culture relies on embedding 
endothelial cells within 3D collagen matrix to allow the cells to form a vascular network, which 
resembles the process of vasculogenesis during embryonic development rather than the process 
of angiogenesis (116). Therefore, the role of Cdc42 to mediate branching morphogenesis in 
angiogenesis remains to be explored. Here, using a previously developed Angiochip (281), where 
endothelial cells are triggered to sprout from a biomimetic blood vessel, we sought to investigate 
the effects of Cdc42 on the morphogenesis of angiogenesis. Unlike other studies of tubulogenesis 
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and Matrigel assays, where endothelial cell network formation occurred in a uniform distribution of 
biochemical stimuli, which makes it challenging to address biological significance of Cdc42 on 
chemotactic migration in angiogenesis, our AngioChip employed a biochemical gradient not only 
to stimulate formation of multicellular sprout structures but it also allows us to unveil the effects of 
Cdc42 in the context of chemotactic migration in angiogenic sprouting. Additionally, we were able 
to tune the amount of Cdc42 pharmacological inhibitor to investigate a more complex role of Cdc42 
within cytoskeleton dynamics. We observed the many facets of Cdc42 to mediate the 
morphogenetic processes of angiogenesis in our study.  
 
3.3 Materials and Methods 
Device Fabrication. As previously reported, devices were fabricated from two layers of 
poly(dimethylsiloxane) (PDMS; Sylgard 184; Dow-Corning) (281). They were treated with plasma 
etcher, bonded together and adhered to a 25mm square glass coverslip. After treatment with 
0.1mg/ml poly-L-lysine (Sigma) for 1hr, they were treated with 1% glutaraldehyde for 1hr and 
washed several times with H2O. Rat tail collagen 1 (2.5mg/ml, Corning) was pipetted into the 
devices with two 400µm diameter acupuncture needles. Upon gelation, the needles were extracted 
leaving two hollow cylindrical channels within the collagen matrix. 
Cell Culture. Human umbilical vein endothelial cells (HUVECs) (Lonza) were cultured in 
EGM-2. HUVECs were seeded into the channel at 3x106 cells/mL as previously described. After 
seeding was complete, devices were immediately placed on a platform rocker (BenchRocker, 
BR2000). 
Angiogenic Sprouting Assay. A combination of angiogenic factors including vascular 
endothelial growth factor (VEGF, 75ng/ml, R&D), monocyte chemotactic protein-1 (MCP-1, 
75ng/ml, R&D), sphingosine-1-phosphate (S1P, 500nM, Cayman Chemical) and Phorbol Myristate 
acetate (PMA, 10ng/ml, Sigma) were administered the next day after cell seeding. The cocktail of 
angiogenic factors was refreshed daily as previously described. 
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Inhibition of Cdc42 Experiment. The next day after cell seeding, Cdc42 inhibitor (ML141, 
15µM, Millipore) was added on the same day that sprouting was started. ML141 was administered 
in both the biomimetic blood vessel and in the angiogenic source channel. Devices were either 
treated with DMSO as control or ML141 over a course of 4 days before they were fixed and stained 
for confocal imaging. Devices were always placed on rocker to provide shear forces in the channels 
over the entire course of experiments. For filopodia experiment, 22.5µM ML141 was added for 4 
hours before they were fixed for quantification (N=4 samples per conditions). 
Immunofluorescence and Confocal Image Acquisition. After fixation, devices were 
permeated with 0.1% Triton-X (Sigma) for 30min and proceeded to incubation with Phalloidin Alexa 
488 (1:200, Invitrogen) overnight in the cold room. Devices were washed several times with 1xPBS 
till fluorescent background was negligible before image acquisition. Confocal images were acquired 
with 40x water immersion objective, Axiovert 200M inverted microscope (Zeiss), and spinning disk 
confocal scan head. Images were acquired in a tiling mode and later stitched using ImageJ. 
Quantification of Sprout Length, Sprout Density, Sprout Angle, and number of 
Invading Cells. To quantify sprout length and density, custom MATLAB code was written to 
measure the individual distances from the leading protrusions of tip cells to the wall of the parent 
vessel, and to count the number of sprouts. Sprout angle was determined as the angle from which 
the sprout deviates from the vertical direction of the gradient between the two channels. ImageJ 
was used to count the number of cell nuclei from projection of z-resolved confocal stacks. (N = 4 
samples per condition). 
Quantification of Branches and Intersegmental Branches. Adopting the custom 
MATLAB code from quantification of sprouts, we quantified number of branches and intersegmental 
branches and their respective lengths. A branch length was defined as the distance from the tip of 
the branch to the end of the branch on the sprout trunk whereas intersegmental branch length was 
defined as the distance connecting the two ends of the intersegmental branch on two separate 
sprouts. 
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Filopodia Quantification. A custom MATLAB code was used to determine the distance 
from the tips of filopodia to where it originates on the cell body from projections of z-resolved 
confocal stacks. The number and length of filopodia were averaged over the number of tip cells in 
each sample. Filopodia angle was measured as the angles in which filopodia deviate from the 
vertically perpendicular line between the 2 channels. (N=4 samples per condition). 
             Statistical Analysis. Sample populations were compared using unpaired, two-tailed 
Student’s t-test or two-sided Wilcoxon rank sum test. *P < 0.05 was the threshold for statistical 
significance. Data points on the graphs represent average values and error bars depict SEM. * 
indicates P<0.05; *** indicates P < 0.001. 
 
3.4 Results 
Inhibition of cdc42 reduced migration speed 
To elucidate the role of Cdc42 in angiogenesis, we employed a biomimetic angiogenic 
model or the AngioChip, which was previously published in our lab (Figure 3.1A). In brief, the 
AngioChip was comprised of two hollow cylindrical channels embedded within a 3D collagen matrix. 
In one of the channels, we seeded endothelial cells and allow them to form an endothelium. In the 
second channel, we administered a cocktail of angiogenic factors, which established an angiogenic 
gradient to trigger sprouting into the 3D collagen matrix (281). To inhibit Cdc42 activity, we used a 
pharmacological inhibitor ML141 (282, 283). We observed that complete inhibition of Cdc42 led to 
cell death. However, sprouting morphogenesis typically occurred over a course of 3-4 days in our 
AngioChip. Therefore, to observe the function of Cdc42 in morphogenesis, we targeted a 50% 
decrease in Cdc42 activity (Figure 3.1B). We administered the inhibitor at the beginning of cocktail 
addition in order to investigate the effects of Cdc42 from the onset of sprouting till formation of 
multicellular sprouts. Partial inhibition of Cdc42 activity significantly decreased the invasion depth 
of sprout tip cells into the interstitial matrix (Figure 3.1C). Cell migration speed was subsequently 
diminished (Figure 3.1D). Interestingly, the appearance of angiogenic sprouts appeared similarly 
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between DMSO control and in Cdc42 inhibition under phase contrast images over a course of 4 
days (Figure 3.1E). 
   
Figure 3.1. Inhibition of Cdc42 in AngioChip. (A) Device schematic. 2 channels fully embedded 
inside 2.5mg/ml Collagen gel. (B) Cdc42 activity was reduced in half with Cdc42 inhibitor ML141.  
(C) Average invading distance of tip cells into matrix guided by a gradient of angiogenic cocktail 
including MCP-1, VEGF, PMA, and S1P. (D) Average invading speed of tip cells over 4 days. (E) 
Representative images of sprouts at Day 4 for control DMSO and Cdc42-inhibited devices. N=4; * 
indicates significant difference (P≤0.05); ns indicates no significant difference. 
 
Inhibiting Cdc42 diminished sprout density and sprout length 
To further characterize the changes in the morphogenesis of angiogenesis upon Cdc42 
inhibition, we utilized confocal microscopy to capture high resolution images of sprouting and 
quantify the number of sprouts and average sprout length. Partial inhibition of Cdc42 =slightly 
decreased the number of sprouts per unit area (Figure 3.2A). However, the average sprout length 
was significantly reduced in half (Figure 3.2B). 
Cdc42 has been shown to regulate cell polarity, one of the many important aspects of cell 
migration (156). Thus, inhibition of Cdc42 results in non-persistent migration in 2D (282). Our 
67 
 
previous results also showed a slight decrease in migration distance and speed, which may be a 
result of non-persistent migration. To verify this, we decided to measure the average sprout angle. 
We postulated that tip cells with non-persistent migration may continuously change directions as 
they migrate towards the source and thus the angle of sprout (Figure 3.2D) may be larger. To our 
surprise, average sprout angle remained unchanged, which revealed that inhibition of Cdc42 didn’t 
affect chemotactic migration towards a gradient of angiogenic cocktails in our biomimetic model of 
angiogenic sprouting but rather directly affected the invasion speed. 
 
 
Figure 3.2. The effects of Cdc42 on sprout length and density during angiogenesis sprouting. (A) 
Quantification of sprout density between control DMSO and Cdc42 inhibition. ML141 was initiated 
at onset of sprouting for 4 days. (B) Sprout length was quantified at day 4.  (C) Representative 
confocal images of sprouting in DMSO and ML141 devices at day 4. (D) Average sprout angle was 
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quantified between DMSO and ML141 devices. N=4; * indicates significant difference (P≤0.05); ns 
indicates no significant difference. 
 
Inhibition of Cdc42 decreased collective cell migration 
To our surprise, the fact that inhibition of Cdc42 activity had a stronger effect on sprout 
length but less so on the invasion depth prompted us to further investigate the extent of cellular 
invasion. From our previous work, different invasion modes (single cell and collective cell migration) 
were observed in our system. Therefore, we characterized the extent of single and collective cell 
migration. We observed the presence of more single cells at the invading front when we inhibited 
Cdc42 activity (Figure 3.3A,B). We also observed a significant reduction in the number of invading 
cells into the 3D interstitial collagen matrix (Figure 3.3C). Interestingly, among these migrating cells, 
we found a significant elevation in the number of single cell migration (Figure 3.3D). Taking 
together, this unveiled that inhibition of Cdc42 activity reduces the extent of cellular invasion and 
collective cell migration of angiogenic sprouting. 
 
Figure 3.3. The effects of Cdc42 on collective migration of endothelial cell sprouting. (A) 
Representative image of cellular invasion in control DMSO device at day 4. (B) Representative 
image of cellular invasion in Cdc42-inhibited device at day 4.  (C) The number of invading cells 
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quantified at day 4 between DMSO and Cdc42-inhibited conditions. (D) The percentage of single 
migrating cells quantified at day 4 between DMSO and Cdc42-inhibited conditions.  N=4; * indicates 
significant difference (P≤0.05). 
 
Cdc42 regulates branching morphogenesis of angiogenic sprouting 
One of the many important morphogenetic processes of angiogenesis is the formation of 
vessel branches (168, 273). As previously reported, branching was evidenced in our AngioChip 
(281). To further identify the morphogenetic differences of sprouts during angiogenic sprouting 
upon inhibition of Cdc42 activity, we quantified the formation of branches with confocal images. 
Occasionally, we also observed tip cells that fuse to another multicellular sprout structure from the 
parent vessel as demonstrated in the schematic (Figure 3.4A). In our model, a majority of sprouts 
exhibited formation of one single branch (Figure 3.4B). Inhibition of Cdc42 significantly reduced the 
number of branches in sprouts (Figure 3.4C). Occasionally, we also observed intersegmental 
branches that connect two individual sprouts through a multicellular tubular structures, which we 
called intersegmental branches. These intersegmental branches appeared to be significantly less 
as Cdc42 was inhibited (Figure 3.4E). Surprisingly, the length of both branches and intersegmental 
branches remained to be unaffected upon inhibition of Cdc42 activity (Figure 3.4D,F). 
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Figure 3.4. The effects of inhibiting Cdc42 on branching morphogenesis of angiogenic sprouting. 
(A) A schematic of difference branching structures and sprout morphology observed in angiogenic 
sprouting in the AngioChip guided by a cocktail of MCP-1, VEGF, PMA, and S1P. (B) Number of 
branch points is quantified for DMSO vs ML141 conditions.  (C) The number of sprouts with 
branches between DMSO and ML141 conditions. (D) Average branch length for DMSO and ML141 
conditions.  (E) Percentage of intersegmental branches for DMSO and ML141 conditions. (F) 
Average length of intersegmental branches in DMSO and ML141 conditions.  N=4; * indicates 
significant difference (P≤0.05); ns indicates no significant difference. 
 
Effects of Cdc42 inhibition on filopodia formation 
To further understand the role of Cdc42 to significantly abate the formation of branches, 
we carefully studied the formation of filopodial extensions as Cdc42 has been demonstrated to 
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regulate the formation of filopodia formation in other cell types including fibroblasts, and neuronal 
cells (284-286). Filopodia are protrusive extensions predominantly present in leading tip cells of 
branch tip and sprout tip cells. We treated Day 3 multicellular sprout structures with defined tip cells 
(Figure 3.5A,i) for a short and acute dose of inhibitor ML141. Short and acute treatment of Cdc42 
inhibitor on invading angiogenic sprouts with multiple extensions in tip cells revealed changes in 
filopodia appearance (Figure 3.5A,i and ii). Surprisingly, acute exposure to Cdc42 inhibitor didn’t 
affect the angle of filopodial extensions (Figure 3.5B). Unexpectedly, inhibition of Cdc42 doubled 
the number of filopodial extensions in tip cells (Figure 3.5C). The distribution of filopodia number 
per tip cells appeared to maintain a similar distribution between control DMSO and Cdc42 inhibition 
conditions but shifted to where there was higher filopodia number/tip cell (Figure 3.5D). Additionally, 
we observed an increase in the percentage of filopodia smaller than 10µm (Figure 3.5F) whereas 
there was no noticeable change in filopodia-like protrusions larger than 10µm. This ultimately led 
to a significantly smaller average length of filopodia in tip cells as Cdc42 activity was inhibited 
(Figure 3.5E). 
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Figure 3.5. Filopodia formation of endothelial cell sprouting upon Cdc42 inhibition. (A) 
Representative confocal images of phalloidin-stained sprout tip cells showing filopodial extensions 
in DMSO and ML141 conditions. Sprouting was initiated for 3 days before 22.5µM ML141 was 
added for 4hrs before fixation. (B) Average angle of filopodia of sprout tip cells was quantified for 
DMSO vs ML141 conditions.  (C) The number of filopodial extensions per sprout tip cells for DMSO 
and ML141 conditions. (D) Histogram of filopodial extension numbers per sprout tip cells for DMSO 
and ML141 conditions.  (E) Average length of filopodial extensions is quantified for DMSO and 
ML141 conditions. (F) Histogram of filopodial extension length for DMSO and ML141 conditions.  
N=4; * and *** indicate significant difference P≤0.05 and P < 0.001, respectively. 
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3.5 Discussion 
While Cdc42 has been identified as an important regulator of many cellular processes such 
as control of cell division, establishment of cellular polarity, and formation of filopodia in 2D cell 
culture (156, 287), its role in endothelial cells, especially, in 3D settings has only been explored in 
details at the initiation and formation of lumen during tubulogenesis (288, 289). Using our 
biomimetic blood vessels where endothelial cells were triggered to sprout by a defined chemical 
gradient, our study suggests that inhibition of Cdc42 also affects the formation of branches of 
endothelial cell sprouts. 
It has been shown that Cdc42 is an important regulator of chemotaxis. Though the role of 
Cdc42 in chemotaxis is possibly cell-type dependent. For example, mouse embryonic fibroblasts 
and hematopoietic stem cells without Cdc42 failed in directed migration, whereas directed migration 
was unaffected in Cdc42-null fibroblastoid cells (290). In our study, inhibition of Cdc42 had a mild 
effect on migration speed but appeared to be unaffected in chemotactic migration. In fact, 
persistency of migration as quantified through sprout angles remained unchanged when Cdc42 
was inhibited. This suggested that Cdc42 inhibition appeared to impair migration speed rather than 
chemotaxis. This observation is in agreement with a previous report where Cdc42 and Rac regulate 
migration speed but not direction of migration towards a gradient of PDGF (291). In addition to the 
role of Cdc42 effect on cell migration, we also observed that its activity also contributed to 
cytoskeletal arrangement ultimately leading to extension of sprouts and extension of filopodial 
protrusions. 
During lung development, Cdc42 directly regulates polarity and its activity is heightened at 
the active budding sides (292). Consequently, disruption of Cdc42 by genetic knockout causes 
abnormal Cdc42 activity on the epithelial cell layer and ultimately reduces epithelial cell budding 
during lung morphogenesis (292). Similarly, in endothelial cell sprouting from an endothelium, 
quiescent endothelial cells first need to reverse polarity to become tip cells (293). As a result, a 
disruption of polarity signaling may potentiate abnormal morphogenesis. Our result demonstrated 
that inhibition of Cdc42 caused a reduction in sprout density, which may suggest a role of Cdc42 
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to contribute to the initiation of tip cells from the endothelium. Similarly, the number of branches, 
where stalk cells have to emerge from sprouts to become tip cells, is also reduced. These results 
indicate that Cdc42 may act through cellular polarity to positively regulate the initiation of tip cell 
formation within an endothelium and within the stalk cells in the trunk of endothelial sprouts. As a 
result, disruption of Cdc42 signaling caused a reduction in the formation of sprouts and branches 
in angiogenic sprouting in our AngioChip.  
Interestingly, if Cdc42 positively mediates the formation of sprout and branches, its activity 
appeared to negatively regulate the initiation of filopodia formation. In our organotypic model, 
inhibition of Cdc42 significantly upsurged the number of filopodia in tip cells. This result appeared 
to contradict other reports in which inhibition of Cdc42 prevented formation of filopodia in 
fibroblasts, and neurons (156, 285). This suggests that Cdc42-driven filopodia formation may be 
cell type-specific. Additionally, most studies often examine a particular biochemical stimulus to 
activate Cdc42 for filopodia bursts in endothelial tip cells. For example, a previous study in caudal 
migration of endothelial cells in zebrafish indicated the role of Bmp signaling to mediate filopodia 
outgrowth (294) whereas another study suggested the function of ECM to induce activation of 
Cdc42 to promote filopodia formation through VEGF-independent NRP1 signaling in zebrafish and 
angiogenesis in mouse retina (295). In contrast, our biomimetic model employed a cocktail of 
different angiogenic factors to trigger sprouting, which may be a factor contributing to the 
discrepancy. 
During angiogenic sprouting events, endothelial cells need to establish apical-basal 
domains to mature into a lumenized blood vessels. At the same time, they need to maintain cell-
cell junction between tip-stalk and stalk-stalk cells to form multicellular structures. In 3D endothelial 
cell tubulogenesis, a previous study has reported the role of Cdc42 to mediate lumen formation 
through Par3, Par6 and PKC complexes (289). Here, in our model, we observed a role of Cdc42 to 
regulate collective cell migration. Disruption of Cdc42 encouraged migration of single cells. This 
suggests another important role of Cdc42 to not only regulate the cellular polarity during lumen 
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formation but also to target and maintain the junctional complexes between cell-cell during 
angiogenic sprouting.  
In conclusion, using an organotypic model of angiogenesis in which sprouting emanate 
from an endothelium under a defined biochemical gradient, we characterized the effects of Cdc42 
on angiogenic sprouting. In our angiogenic model, Cdc42 appeared to regulate migration speed, 
branching morphogenesis, and filopodia formation. Interestingly, we also observed the many facets 
of Cdc42 activity depending on the morphogenetic processes that Cdc42 targets. For example, 
Cdc42 positively initiates sprout formation but negatively mediates filopodial initiation. In addition, 
it contributes to the extension of sprout length but appears to have no effect on branch length. 
Further studies need to address its activity to mediate and maintain vascular junction to support 
collective cell migration. 
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CHAPTER 4: A PRECLINIAL ORGANOTYPIC MODEL TO EXAMINE VASCULAR 
INVASION AND VASCULAR REPLACEMENT IN PANCREATIC DUCTAL 
ADENOCARCINOMA 
  
4.1 Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is often not detected until it has already spread 
significantly into surrounding tissues and metastasized to distant sites (296). However, it remains 
unclear how the PDAC cells interact with the blood vessel during vascular invasion to metastasize. 
Here, we describe a preclinical organotypic PDAC-on-a-chip to examine the vascular invasion of 
PDAC. [Need a sentence that actually describes the model – something like “Tumor cells are 
seeded in a 3D matrix wherein an engineered endothelialized lumen is juxtaposed>” In this model, 
we reveal a striking phenomenon where PDAC cells invaded into the blood vessel, induced 
apoptosis in the endothelial cells and replaced the endothelial cells in blood vessels. This 
phenomenon was confirmed in a model of ectopic tumor growth.  We further identified ALK7 as a 
critical mediator of vascular replacement in PDAC. Blocking ALK7 diminished tumor cell 
proliferation and ultimately inhibited vascular replacement. Our study unveils ALK7 as a potential 
therapeutic target to prevent vascular replacement during vascular invasion in PDAC. 
  
4.2 Introduction 
 Although the detection and treatment of cancer in its earliest stages has significantly 
improved outcomes in many confined tumors, survival rates for tumors that have spread to distant 
sites remains dismal (297). As such, the vast majority of cancer mortalities stem from metastasis 
and its complications (298, 299). Metastasis is a final product of a chain of complex multiple steps 
including local spread of cancer cells at primary sites of origin, invasive entry into nearby 
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vasculature (intravasation), and dissemination and growth at distant organ sites (224, 300). The 
interactions between tumor cells and blood vessels in particular are poorly understood, despite the 
importance of these interactions to many steps of the metastasis cascade.  
In part, the lack of detailed understanding of these tumor-vessel interactions is because it 
is difficult to observe these interactions in models of tumor invasion.  In vivo studies of tumor growth 
in mice have made important observations of tumors near vascular structures, based on histologic 
evidence, and a few studies have attempted to observe these events through intravital microscopy. 
For instance, metastatic breast cancer to the brain after extravasation remained closely adhered to 
the vessels to avoid apoptosis induced by astrocyte-secreted serpin proteins (301). Recent 
attempts to use in vitro cultures to model these interactions have suggested the importance of 
juxtaposing tumor cells with vessel-like structures such as endothelial cell-lined lumens in order to 
model processes such as extravasation or intravasation (302, 303). Here, we apply such 
engineered 3D models of vessels to study the interactions of such vascular structures with 
pancreatic ductal adenocarcinomas. These tumors are reportedly highly avascular, with a paucity 
of endothelial cells within these tumors (185, 304).  
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic cancer whose cancer 
cells have been shown to escape the tumor and enter into the circulation at very early stage of the 
tumor progression (296, 305, 306). One of the hallmarks of advanced PDAC is local invasion of the 
tumor onto the nearby hepatic veins, arteries, and mesentery blood vessels (307). Vascular 
invasion is an important parameter to determine resectability of the tumor (236). It also contributes 
to the dismal 5-year survival rate below 7% of PDAC (307). It is also an initial step to enable entry 
of tumor cells into the circulation, resulting in circulating tumor cells that are present in the blood 
stream before lesions are detectable in PDAC (305). Yet, these tumors are reportedly highly 
avascular, with a paucity of capillary vessels within these tumors (185, 304). Thus, it appears that 
PDAC exhibits unusual yet important features in its interactions with vessels. Here, we describe a 
model system in which a biomimetic ductal channel containing PDAC cells is juxtaposed to an 
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engineered rudimentary blood vessel consisting of an endothelialized, perfused lumen.  Using this 
model, we investigated PDAC invasion and interactions at the blood vessel interface. Our model 
revealed a striking phenomenon where blood vessels were replaced by the PDAC cells. We also 
provided a mechanistic study to unveil Nodal/Activin-mediated signaling through ALK7 receptor to 
enhance PDAC proliferation to permit de-endothelialization of blood vessel during vascular 
invasion. 
  
4.3 Materials and Methods 
Cell culture. Primary murine pancreatic cancer cells (a gift from Dr. Stanger, University of 
Pennsylvania) were isolated from primary tumors of GEMM (Kras-G12D p53-/- YFP) and cultured 
in DMEM + 10% fetal bovine serum + L-glutamine + Gentamycin. Human pancreatic cancer cell 
lines, Panc-1 (a gift from Dr. Faller, Boston University) and BxPC-3 (a gift from Dr. Stanger, 
University of Pennsylvania) were cultured in DMEM + 10% FBS + 1% Pen/strep and RPMI1640 + 
10% FBS + 1% Pen/Strep respectively. HUVECs were cultured in EGM-2 (Lonza). EGM2 was used 
in all coculture experiment unless indicated otherwise.  
 Device fabrication and 3D organotypic PDAC experiments. Devices were fabricated as 
previously described (281). Briefly, our organotypic PDAC on a chip was comprised of 2 
polydimethylsiloxane (PDMS) gaskets cast from silicon wafer masters. The gaskets were bonded 
after plasma etching and treated with 0.1mg/ml poly-L-lysine (Sigma) overnight and subsequently 
treated with 1% glutaraldehyde (EMS) as previously described. 2.5mg/ml rat tail collagen I 
(Corning) was pipetted into the devices after 2 acupuncture needles were placed in the gaskets. 
Needles are either 1mm or 500µm apart. PDAC cells were seeded at 2x106 cells/ml in EBM2 
(Lonza) and HUVECs were seeded at 3x106 cells/ml in EGM-2 (Lonza) as previously described 
(281). Devices were plated on platform rocker. Media in blood vessel channel containing an 
additional 10%FBS + EGM2 was added into blood vessel channel to induce migration of PDAC 
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cells. PDAC channel was cultured in EBM2. All media was refreshed daily. SB431542 (Tocris) was 
used at 5µM concentration and added into both channels. 
 Immunofluorescence staining in 2D cultures. Samples were fixed with 4%PFA and 
permeated with 0.1% Triton-X. Samples were blocked with 3%BSA and subsequently incubated 
with primary antibodies: anti-CD31 (Dako, 1:200), anti-GFP (Abcam, 1:500), anti-cleaved caspase 
3 (Cell Signaling, 1:500) and DAPI (Sigma, 1:500). All secondary antibodies (Invitrogen) were used 
at 1:1000. 
Cell imaging and quantification in 3D devices. Migration of PDAC in 3D organotypic 
model was captured using bright field. Invasion distance was measured using a custom Matlab 
code to determine the distance from the tip of the invasive front to the biomimetic PDAC duct. For 
quantification of PDAC invasion area on biomimetic blood vessel, devices were fixed with 4%PFA, 
permeated and blocked with 3%BSA overnight. Primary antibodies for anti-CD31 (Dako, 1:200), 
anti-GFP (Abcam, 1:500), anti-cleaved caspase 3 (Cell Signaling, 1:500), and Dapi (Sigma, 1:500) 
were all incubated overnight at 4oC. Primary antibodies were washed overnight. Secondary 
antibodies (Invitrogen, 1:500) were incubated overnight and devices were washed over a few days 
to remove background before confocal microscopy. Confocal images were acquired with spinning 
disk confocal microscope. Z projection of image stack was used to quantify the area of blood vessel 
replaced by PDAC. 
2D co-culture experiment for apoptosis. HUVECs were seeded into 96 well plate at 
17000cells/well overnight to obtain a confluent monolayer. PDAC cells were seeded at 4200 
cells/well over HUVECs. Apoptosis was determined via active caspase activity quantified by 
apoptosis bioluminescence kit (Promega), following the manufacturer’s instruction. 
Bioluminescence intensity of activate caspase was acquired using SpectraMax5. Tumor-
conditioned media were collected from coculture of 500000 HUVECs and 130000 PD7591 
overnight in 1.5ml EGM2 in wells of 6 well plate and immediately used in experiment. Neutralizing 
antibodies for TNFα, FasL, Trail and their respective control antibodies were used at 25µg/ml. 
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Neutralizing antibody for pan-TGFβ (R&D) and its respective antibody control (R&D) were both 
used at 100ug/ml 
 PDAC vascular invasion in 2D heterotypic patterning coculture. Annulus rings were 
cut out by using biopsy hole punches (2mm and 3.5mm diameter) from a PDMS slab. Annulus rings 
were placed in the center of wells in 24 well plate. 10000 PDAC cells were seeded inside the 
annulus ring while HUVECs were subsequently seeded at 150000 cells outside the annulus rings 
overnight. Annulus rights were peeled off the next day and cells were allowed to grow into contact 
for 2-3 days after removal of annulus rings. Multiple overlapping images of YFP PDAC cell islands 
were imaged using TE200 microscope (Nikon). Overlapping images were stitched using ImageJ 
and PDAC areas were quantified using ImageJ. 
Tumor xenograft model. Under anesthesia (standard isoflurane inhalation) pancreatic 
cancer cell line (PD7591) was subcutaneously inoculated into the dorsal area of the athymic nude 
mouse (NCr-nu/nu, 4-5 week, female) by using regular insulin syringes. The cancer cells were 
resuspended in 1:1 mixture of cancer cell growth medium and Matrigel (high protein concentrated 
form) kept in ice. Two million cancer cells in 100 μL mixed solution were rapidly injected per animal. 
Mice were monitored daily after the tumor injection and the size of growing tumors was measured 
with a caliper every two days. The tumor volume was calculated with an equation: 0.52 x (AxB2), 
where ‘A’ is a long axis and ‘B’ is a short axis of the tumor. Tumors were allowed to grow to a 
maximum volume of 2000 mm3
 
in all cases as consideration for the animals’ welfare. All procedures 
were performed in the sterile environment of a laminar flow cabinet housed in the animal facilities 
area in Charles River Campus (CRC) animal facility at Boston University. When the tumors reach 
a certain size, the tumors were excised to examine tumor microenvironment and tumor invasion to 
blood vessels. The animals were sacrificed using the standard carbon dioxide euthanizing method 
or the secondary physical (cervical dislocation) method. 
Tumor tissue processing and immunofluorescence staining. Excised tumors were 
rinsed in PBS, and fixed in 4% formalin for 18 hours at room temperature, then stored in 100% 
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methanol at -20°C. For immunofluorescence, the fixed tumors were placed in 30% sucrose solution 
in PBS, incubated overnight at 4°C, and frozen in the Tissue-Tek Optimal Cutting Temperature 
(O.C.T.) compound (Sakura, Tokyo, Japan). Sections of 10-μm thickness were cut at -20°C. Some 
other cases, we cut small pieces of tumors using blades for whole mount staining. After blocking 
with 5% normal goat serum (Jackson ImmunoResearch, West Grove, PA) in PBST (1X PBS with 
0.3% Triton) overnight at 4°C, the sections were treated with one or more of the following primary 
antibodies overnight at 4°C: rabbit anti-cleaved caspase 3 (1:100, Cell Signaling), rat anti-mouse 
CD31 (1:100, BD Pharmingen), rat anti-TER119 (1:100, Santa Cruz) antibodies. After rinses with 
PBS overnight at 4°C, sections or whole mount tumor pieces were incubated overnight at 4°C with 
one or more of the secondary antibodies: fluorescein isothiocyanate (FITC)-conjugated goat anti-
GFP antibody, rhodamine-conjugated goat anti-rat antibody, Alexa 647-conjugated goat anti-rabbit 
antibody (1:500, all three from Jackson ImmunoResearch). DAPI (4',6-diamidino-2-phenylindole, 
1:10,000, Roche, Indianapolis, IN) was also included in the secondary antibody solution. Rinsed 
samples were mounted with the ProLong Gold anti-fade reagent (Invitrogen, Carlsbad, CA). 
Fluorescent signals were visualized and digital images were obtained, using a LEICA confocal 
microscope.  
Statistical Analysis. Sample populations were compared using unpaired, two-tailed 
Student’s t-test. *P < 0.05 was the threshold for statistical significance. Data points on the graphs 
represent average values and error bars depict SEM.  
  
4.4 Results 
A model of PDAC on a chip reveals 3D invasion and vascular replacement 
To examine the process of PDAC invasion toward engineered blood vessels, we 
engineered an organotypic model of pancreatic ductal adenocarcinoma (PDAC) on a chip building 
on a previously developed vessel on a chip (281). Briefly, our PDAC organotypic model is 
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composed of two hollow cylindrical channels, which are completely embedded into collagen matrix 
(Figure 4.1A). In one of the channels, we seeded endothelial cells to form a biomimetic blood vessel 
as previously discussed (281). In a parallel channel, we seeded pancreatic cancer cells and allowed 
them to adhere to form a monolayer of epithelial cells to mimic a ductal compartment of pancreatic 
duct. In order to observe the interactions of pancreatic ductal adenocarcinoma with the blood 
vessels, we stimulated migration of the pancreatic cancer cells with a gradient of 10% FBS, a 
commonly used method to investigate migration of cancer cells. FBS was administered into the 
endothelium channel and refreshed daily.  
Upon stimulation with FBS, the pancreatic adenocarcinoma cells in the biomimetic ductal 
channel began to proliferate and lost their polarity and pile on top of one another to form a multilayer 
of cells. By day 4, PDAC cells began to invade into the matrix towards endothelial lumen. The 
invasion was collective with epithelial cells remaining in contact with each other with branched 
structure reminiscent of epithelial morphogenesis (Figure 4.1B). As we maintained the FBS 
gradient, the pancreatic cancer cells continued to approach the engineered blood vessel. Upon 
contact with the biomimetic blood vessel, they wrapped around the blood vessel and spread along 
the length of the blood vessel (Figure 4.1C). Intriguingly, during PDAC invasion, we observed part 
of the blood vessel was de-endothelialized and replaced by the PDAC cells (Figure 4.1D). We first 
observed de-endothelialization of blood vessel in primary mouse PDAC cell line PD7591 but later 
also identified 3 additional primary mouse PDAC cell lines and human pancreatic cancer cell line 
producing the same result (Supplementary Figure 4S1). 
Close examination of the interface between PDAC and endothelium on the luminal surface 
of the vessel, we observed dying endothelial cells, marked by active caspase-3 in proximity to the 
area where pancreatic cancer cells have invaded onto the blood vessel (Figure 4.1E). To 
investigate whether our model has revealed an in vivo process that occurs in the pancreatic tumor 
environment, we subcutaneously inoculated the same tumor cells into nude mice. After the tumor 
reached 400mm3, we sacrificed the mice and resected the tumor including the adjacent area around 
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the tumor. Interestingly, we also observed a scarcity of blood vessels in the vicinity of the tumor 
region (Figure 4.1F), consistent with observations reported in genetically engineered mouse 
models and human pancreatic tumors (185). Among the small number of intratumoral blood 
vessels, a majority of endothelial cells were positive for active caspase-3, and some adjacent blood 
vessels near the peripheral tumor were also positive for active caspase 3 (Figure 4.1F).  
 
Figure 4.1. Preclinical organotypic model for PDAC-on-a-chip to capture vascular invasion and 
vascular replacement. (A) Schematic of PDAC-on-a-chip with a biomimetic blood vessel and a 
pancreatic cancer duct. Phase image shows cells seeding after 1 day in culture (B) Average 
invasion distance of PDAC cell line PD7591 towards a gradient of FBS with and without HUVECs. 
Addition of HUVECs increases migration speed of PD7591. (C) PD7591 invaded towards blood 
vessel, migrated along the vessel and wrapped around the blood vessel. (D) Confocal image of a 
section of the blood vessel invaded by PD7591 showed that part of the blood vessel was de-
endothelialized. (E) PDAC caused apoptosis in endothelial cells in the blood vessels in PDAC 3D 
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organotypic model. (F) Endothelial cells were also apoptotic in the tumor in a xenograft model in 
vivo 
 
PDAC vascular invasion induces endothelial cell apoptosis through TGF-β 
signaling. 
We next sought to identify which signaling pathways that caused endothelial apoptosis. 
We employed a 2D heterotypic co-culture of PDAC cells and endothelial cells by interspersing 
PDAC cells on top of a monolayer of endothelial cells (Figure 4.2A). Overnight incubation revealed 
a significant number of apoptotic endothelial cells in proximity to the pancreatic cancer cells while 
pancreatic cancer cells were all negative for active caspase 3 (Figure 4.2A), which is also 
consistent with our organotypic model and in vivo xenograft model. TGF-β, TNF-α, FasL, and Trail 
have been shown to induce apoptosis in different cell types (308-312). We sought to identify which 
of these apoptotic pathways may be involved in endothelial apoptosis in 2D heterotypic coculture 
with PDAC cells. After PDAC cells were plated for 24hrs with or without inhibitor of each of these 
four common apoptotic pathways, we quantified the active caspase activity. Blocking Trail, FasL, 
or TNF-α signaling with neutralizing antibodies didn’t prevent apoptosis. However, inhibition of 
TGF-β signaling with SB431542 (313) significantly prevented apoptosis of endothelial cells in 2D 
heterotypic co-culture with PDAC cells (Figure 4.2B). 
To examine the effectiveness of blocking TGF-β signaling to prevent de-endothelialization 
in our 3D organotypic PDAC on-a-chip model, we allowed pancreatic cancer cells from the 
pancreatic cancer duct to invade to the engineered blood vessel. Once the pancreatic cancer cells 
landed on the blood vessels, we started 5µM SB431542 treatment for a duration of 7 days. 
Interestingly, we also found that blocking TGF-β signaling significantly prevented pancreatic cancer 
cells to de-endothelialize our biomimetic blood vessel (Figure 4.2C).  
We further investigated whether inhibition of TGF-β signaling also led to less vascular 
apoptosis in vivo by subcutaneously injecting the same pancreatic cancer cell line PD7591 into 
mice. By day 9, when the tumor reached 100mm3, we started to administer SB431542 and control 
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vehicle into two groups of mice through peritoneal injection daily for 1 week. Interestingly, tumor 
growth didn’t decelerate in response to SB431542 (Figure 4.2D), in agreement with previous 
studies (222, 223). Remarkably, mice treated with SB431542 for 1 week had less apoptotic 
endothelial cells. Subsequently, these tumors acquired a higher vessel density within the tumor 
microenvironment (Figure 4.2E). This mirror what we uncovered using our preclinical organotypic 
PDAC-on-a-chip. 
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Figure 4.2. Inhibition of TGF-β signaling prohibited vascular apoptosis and vascular replacement. 
(A) Endothelial cells were apoptotic, shown by active caspase 3 staining (white), near the invading 
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pancreatic cancer cells PD7591 in 2D heterotypic coculture. (B) Screening for apoptosis pathways 
revealed TGF-β-mediated apoptosis in endothelial cells. (C) Inhibition of TGF-β signaling with 
SB431542 prohibited vascular replacement in 3D organotypic model. (D) Inhibition of TGF-β 
signaling with SB431542 in tumor xenograft model. Tumor growth didn’t decelerate. (E) 
Quantification of vascular apoptosis and vascular density revealed a significant reduction in 
endothelial cell apoptosis and significantly higher vessel density within the tumor in the xenograft 
model. NS indicates non statistical significance (p>0.05). * and ** indicate statistical significance, 
p<0.05 and p<0.01 respectively. 
 
Vascular replacement is driven through invasion and endothelial displacement by 
PDAC cells. 
To closely examine cellular interactions during vascular replacement, we designed a 2D 
heterotypic pattern coculture to enable careful observation of cell-cell interacts at the interface 
between endothelial cells and PDAC cells. Pancreatic cancer cells were plated inside an annulus 
while endothelial cells were plated outside the annulus ring. Retrieval of the annulus revealed a 
circular pattern of pancreatic cancer cells surrounded by a monolayer of endothelial cells (Figure 
4.3A). Over a period of 6 days, pancreatic cancer cells began to invade outward and took over the 
endothelial cells (Figure 4.3A). When cultured alone, pancreatic cancer cells expanded quickly to 
cover the surface. However, as endothelial cells were present outside, the extent of tumor cell 
invasion dropped drastically, which suggested that pancreatic cancer cells first need to break 
through the barrier of endothelial cell in order to invade outward. Notably, when the co-culture 
pattern was treated with 5 µM SB431542 to inhibit TGF-β signaling, we observed an even more 
significant reduction in the extent of tumor cell invasion, suggesting that SB431542 was effective 
to prevent vascular replacement in our 2D heterotypic pattern coculture. This 2D heterotypic pattern 
coculture appeared to capture the replacement of endothelial cells during invasion of PDAC cells. 
Similarly, we also observed the efficiency of SB431542 to prevent vascular replacement of human 
pancreatic cancer cell lines BxPC-3, and Panc-1 over several days in 2D heterotypic pattern 
coculture (Supplementary Figure 4S2). 
Interestingly, we also observed that there was a significantly high signal of active caspas-
3 in endothelial cells at the interface between endothelial cells and PDAC cells. Treatment with 
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SB431542 significantly reduced the active caspase-3 staining in endothelial cells closely in contact 
with PDAC cells (Figure 4.2B). This observation prompted us to carefully examine the cellular 
dynamics at the interface between PDAC cells and endothelial cells through time lapse movie. 
Remarkably, the PDAC cells appeared to invade and push the endothelial cell front line backward, 
causing the endothelial cells to round up and undergo apoptotic (Supplementary Movie S1). 
Addition of SB431542 to the culture media during time lapse halted the physical invasion of 
pancreatic cancer cells (Supplementary Movie S2). 
 
Figure 4.3. Vascular replacement is driven through invasion and endothelial displacement by 
PDAC cells. (A) Heterotypic pattern coculture of PD7591 and HUVECs. PD7591 was patterned 
inside the annulus while HUVECs were seeded outside the annulus. PD7591 was allowed to invade 
and replace the vascular cells in the presence of DMSO or SB431542. Invasion area of PD7591 
was quantified over 6 days and revealed the effectiveness of inhibition of TGFβ signaling to prevent 
vascular replacement. (B) Apoptotic endothelial cells were more pronounced at the interface 
between pancreatic cancer cells and endothelial cells. SB431542 diminished apoptotic endothelial 
cells in proximity of pancreatic cancer cells. Scale bar is 200 µm. * indicates statistical significance 
(p<0.05).  
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Vascular replacement of PDAC was driven through ALK7-mediated proliferation of 
PDAC cells. 
Since SB431542 has previously been reported as an inhibitor for ALK4/ALK5/ALK7 (313), 
we sought to determine which receptors in each of the cell types contributed to vascular 
replacement. In endothelial cells, treatment with SB431542 significantly reduced the apoptosis of 
endothelial cells (Figure 4.4A). We also knocked out ALK5 in endothelial cells via CRISPR/Cas9 
and observed a similar reduction in apoptosis in endothelial cells (Figure 4.4B). This demonstrated 
that ALK5 was the receptor that regulated endothelial cell apoptosis. To investigate whether ALK5 
KO endothelial cells impede vascular invasion, we plated wild type PD7591 and ALK5 KO HUVECs 
in 2D heterotypic pattern coculture. Interestingly, the quantified invasion area of PD7591 showed 
no difference between ALK5 KO vs scramble HUVECs condition (Figure 4.4C).  This suggested 
that although ALK5 regulated endothelial cell apoptosis, inhibition of ALK5 signaling in endothelial 
cells contributed minimally to PDAC invasion and vascular replacement. 
 
Figure 4. Vascular replacement of PDAC was driven through ALK7-mediated proliferation of PDAC 
cells. (A) SB431542 inhibited apoptosis of endothelial cells (n=3 individual experiments). (B) 
Knocking out ALK5 receptor in endothelial cells suppressed apoptosis of endothelial cells reflecting 
the similar effect of SB431542 (n=3 individual experiments). (C) ALK5 KO HUVECs didn’t 
decelerate PD7591 invasion suggesting that ALK5-mediated apoptosis contributed minimally to the 
vascular replacement in PDAC (n=2 individual experiments). (D) SB431542 reduced proliferation 
of PD7591 (n=3 individual experiments). (E) Knocking out ALK7 receptor in PD7591 suppressed 
proliferation of PD7591 mirroring the similar effect of SB431542 (n=2 individual experiments). (F) 
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Blocking proliferation using 5µg/ml Aphidicolin halted vascular invasion and vascular replacement 
in 2D heterotypic pattern coculture (n=3 individual experiments). * and ** indicate statistical 
significance, p<0.05 and p<0.01, respectively. 
 
On the other hand, SB431542 reduced proliferation of PD7591 (Figure 4.4D). Noticeably, 
using CRISPR-mediated knockout of ALK7 receptor in PD7591, we observed a similar reduction 
in proliferation of PD7591 (Figure 4.4E). This suggested that ALK7 mediated proliferation of 
PD7591. To verify that proliferation is the main contributor of vascular replacement, we employed 
the 2D heterotypic pattern coculture and compared the invasion area of PD7591 with and without 
Aphidicolin, a proliferation inhibitor. Noticeably, we observed a significant reduction in invasion area 
of PD7591 cells when cell proliferation was inhibited (Figure 4.4F). This confirmed out hypothesis 
that ALK7-mediated proliferation of PDAC plays a particularly prominent role to vascular invasion 
and endothelial cell replacement in PDAC. 
 
4.5 Discussion 
In contrast to most tumors, which are hyperangiogenic, human PDAC is poorly 
vascularized (185, 304). Previous studies, using genetically engineered mouse model (GEMM), 
have shown that PDAC is also hypovascular and the tumor has a paucity of vessels with diameter 
larger than 10 µm (185, 304). Interestingly, pancreatic cancer cells are also known to express and 
secrete a plethora of pro-angiogenic factors (314), which raises the question of how these tumors 
end up hypovascularized. Our studies suggest that the lack of intratumoral vasculature in PDAC is 
not a result of reduced angiogenesis per se, but instead a result of endothelial cell apoptosis 
triggered by the invading tumor cells. The ability of these tumors to rapidly invade into the vessel 
lumen and displace the endothelial cells has been observed in human PDAC samples but not with 
chronic pancreatitis (237, 238), and could explain the high rate of CTC and metastatic load of PDAC 
in general. Reportedly, 69.1% of cases of human PDAC with vascular invasion exhibits vascular 
replacement as examined through histological sections of patient samples (238). Similarly, a recent 
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study reported that when ovarian cancer spheroids were plated on a monolayer of endometrium, 
they spread on the surface of the endometrium and displaced the endometrial cells (322). This 
study together with ours demonstrate that tumor cells acquire an efficient capability to clear stromal 
components as they continue to invade and engross the stromal environment. 
Apart from discovering a mechanism to explain hypovascularity in PDAC, our study unveils 
the crucial role of ALK7 signaling to contribute to hypovascularity in PDAC. ALK7 is a receptor for 
both Activin and Nodal (193). The roles of Activin and Nodal are well characterized during 
embryogenesis and especially they also play a role in pancreas development (217). However, its 
pathological activities in diseases, such as in pancreatic cancer have been elusive. A recent study 
has linked Nodal but not Activin to the formation of pancreatic cancer stem cells (222). In addition, 
besides stimulating formation of a rare population of pancreatic cancer stem cells, Nodal has also 
been found to re-express in many human pancreatic cancer cell lines while it is absent in normal 
adult pancreatic epithelial cells. Blocking Nodal diminished liver metastasis in an in vivo liver 
metastasis model of pancreatic cancer (223). Here, we discovered that ALK7 activation stimulates 
proliferation of PDAC cells, likely mediated by Activin and Nodal ligands. CRISPR-mediated 
knockout of ALK7 in the tumor cells abrogated the invasion and replacement of endothelial cells in 
blood vessels. Interestingly, Nodal has also been linked to mediate formation of microvascular 
channels by aggressive and genetically deregulated tumor cells in melanoma (218, 315). These 
findings together with our study suggested that Nodal/Activin-ALK7 is an important signaling to 
promote tumor-blood vessel interactions and inhibiting Nodal/Activin-ALK7 signaling is a potential 
avenue to block vascular invasion and vascular replacement in PDAC. 
 Endothelial cells can be induced to undergo apoptosis via many previously identified 
soluble pro-apoptotic signals such as FasL, TNFα, TGFβ, and Trail to trigger caspase-dependent 
apoptosis. However, the apoptosis of endothelial cells induced by PDAC invasion may be triggered 
through an alternative mechanism that requires proximal physical contact and differential 
proliferation rates between the tumor cells and endothelial cells. Specifically, highly proliferative 
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tumor cells physically invaded and displaced slowly proliferative endothelial cells, leading to 
endothelial cell apoptosis and vascular replacement. Such a phenomenon resonates with a 
classical concept of cell-cell competition, which describes the existence of ‘winner cells’ and ‘loser 
cells’ based on their fitness within the local environment such as their cellular division potential 
(316). For instance, during Drosophila development, Minutes mutated cells experienced slow 
growth rate and were cleared by wild type cells through apoptosis induction (317). These effects 
are not unique to PDAC, as previous studies also observed mammary tumor lines can induce 
apoptosis in HUVECs while normal mammary epithelial cells, fibroblasts, or leukocytes did not 
(318). 
 Here, using our 3D organotypic model, we demonstrate that tumor-endothelial cell 
interactions are not restricted only to intravasation and extravasation, but involve more complex 
processes such as endothelial displacement within the blood vessels. Our simple model of PDAC 
and blood vessels provided sufficient complexity to reveal this process, yet allowed us to introduce 
genetic and spatiotemporal control to isolate receptor pathways involved for each cell type. Going 
forward, such models could be used to capture the behavior of other tumor types as well as 
additional features of tumor progression, such as specific stromal components (ECMs, stromal 
cells, blood vessel components) and immune cells. Although existing in vivo mouse models provide 
great opportunities to capture the progression of cancer, dissecting the molecular mechanisms and 
cell-cell interactions is often difficult due to the complexity of in vivo models. Thus, as demonstrated 
here, 3D organotypic models provide an important complement to understand these complex 
cellular interactions with more mechanistic insight (319). 
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Figure 4.S1. Vascular invasion and replacement were also observed in other murine primary PDAC 
cell lines and human pancreatic cancer cell line in our 3D biomimetic PDAC-on-a-chip model. (A) 
Murine primary pancreatic cancer cell line (MH6883 Clone 4) invaded and de-endothelialized the 
blood vessels. (B) Murine primary pancreatic cancer cell line (PD883) invaded and de-
endothelialized the blood vessels. (C) Murine primary pancreatic cancer cell line (MH6556 Clone 
4) invaded and de-endothelialized the blood vessels. (D) Human pancreatic cancer cell line (Panc-
1) invaded and de-endothelialized the blood vessels. In all images, pancreatic cancer cells are in 
green, HUVECs stained with CD31 in red, and cell nuclei stained with DAPI in blue. Scale bar is 
200µm. Blood vessels were outlined in yellow dash lines. 
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Figure 4.S2. Vascular invasion and replacement of human pancreatic cancer cell lines in 2D 
heterotypic patterning coculture. (A) Human pancreatic cancer cell line Panc-1 and HUVECs were 
patterned in 2D heterotypic coculture with or without 5µM SB431542. SB431542 effectively 
reduced vascular replacement of Panc-1 (n=3 individual experiments). (B) Human pancreatic 
cancer cell line BxPC-3 and HUVECs were patterned in 2D heterotypic coculture with or without 
5µM SB431542. SB431542 effectively reduced vascular replacement of BcPC-3 (n=3 individual 
experiments). * indicates statistical significance (p<0.05), ** indicates statistical significance 
(p<0.01). 
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Table 4.1. Primers for qPCR. 
Primers (5’-3’) 
Human ALK5 (Forward) GCTGTGAAGCCTTGAGAGTA 
Human ALK5 (Reverse) ATGCCTTCCTGTTGACTGAG 
Human TGFβR2 (Forward) TCCTCGTGAAGAACGACCTA 
Human TGFβR2 (Reverse) TAGGACTTCTGGAGCCATGT 
Human TGFβ1 (Forward) CTGTGGCTACTGGTGCTGAC 
Human TGFβ1 (Reverse) GCAGCTTGGACAGGATCTGG 
Human TGFβ2 (Forward) CTGCAGCACACTCGATATGG 
Human TGFβ2 (Reverse) TACTCTTCGTCGCTCCTCTC 
Human TGFβ3 (Forward) TTCCGCTTCAATGTGTCCTC 
Human TGFβ3 (Reverse) TCCTCTGCTCATTCCGCTTA 
Mouse TGFβ1 (Forward) GAGCTGCGCTTGCAGAGATT 
Mouse TGFβ1 (Reverse) ACAGCCACTCAGGCGTATCA 
Mouse TGFβ2 (Forward) CGAGCAGCGGATTGAACTGT 
Mouse TGFβ2 (Reverse) ACAGCGTCTGTCACGTCGAA 
Mouse TGFβ3 (Forward) CACGGTGCTTGGACTATACA 
Mouse TGFβ3 (Reverse) GCTGCACTTACACGACTTCA 
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Table 4.2. Oligo sequences for CRISPR. 
gRNA oligos (5’-3’) 
Human ALK5 oligos CACCGCATACAAACGGCCTATCTCG 
AAACCGAGATAGGCCGTTTGTATGC 
Human ALK7 oligos CACCGTGTGAAGCAGCATTCGGTTT 
AAACAAACCGAATGCTGCTTCACAC 
Mouse ALK5 oligos CACCGTCCGCAGCTCCTCATCGTGT 
AAACACACGATGAGGAGCTGCGGAC 
Mouse ALK7 oligos CACCGCGGTTTGGGGAAGTGTGGCA 
AAACTGCCACACTTCCCCAAACCGC 
Scramble CACCGGCACTACCAGAGCTAACTCA 
AAACTGAGTTAGCTCTGGTAGTGCC 
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CHAPTER 5: CONCLUSION AND FUTURE WORK 
Culture systems to study angiogenesis have evolved from traditional 2D systems to 3D 
systems and to microfluidic platforms to model angiogenesis. Standard 2D culture was first used 
to study endothelial cell migration in wound healing context in 2D. Tube formation on 2D Matrigel 
was also employed to study the network formation of endothelial cells. These assays, however, are 
unable to capture 3D invasion in in vivo angiogenic sprouting (242, 281). Perhaps, one of the most 
robust 3D culture systems for angiogenic sprouting is the microcarrier bead sprouting assay where 
endothelial cells are coated on a microcarrier bead and invade in a 3D manner into the interstitial 
matrix under the guidance of VEGF and additional cues provided by fibroblasts. Although 
microcarrier bead model quite accurately capture the angiogenic invasion in 3D, it is fundamentally 
lacking fluid shear stress, which endothelial cells are constantly under exposure (281). Thus, 
microfluidic platforms for angiogenesis have gained popularity as they not only introduce fluid shear 
forces but also enable better control of shear stress levels. Such a microfluidic platform is typically 
fabricated using standard photo lithography. A microfluidic angiogenesis on a chip fabricated from 
lithography is often comprised of 3 compartments. Two compartments are square rectangular 
channels, located at two sides of a middle compartment where extracellular matrix proteins are 
introduced. Endothelial cells are seeded into one of the square rectangular channels where 
endothelial cells are in contact with ECM proteins on just one vertical wall of the channel and with 
PDMS on the other 3 walls (48, 320-322). By introducing biochemical signals into the non-
endothelialized channel, endothelial cells begin to invade into the interstitial compartment and 
organize into 3D multicellular sprout structures. 
Our AngioChip device also has 3-compartment system that is capable of generating a 
gradient to induce angiogenic sprouting. However, our model has several distinct features that 
enable the study of morphogenetic processes of angiogenesis that might not be accessible by 
using other microfluidic platforms. First, the usage of acupuncture needles permits the creation of 
circular channels that resemble structural features of blood vessels. In contrast, in other microfluidic 
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devices, endothelial cells only sit on a vertical wall of extracellular matrix proteins, which may limit 
studies of how other non-endothelial cell types interact with the blood vessels. For instance, study 
of tumor cell migration along and around the blood vessels, which have been observed in vivo, may 
be challenging in such systems. Secondly, the biomimetic blood vessel in our device is completely 
surrounded by extracellular matrix proteins while other microfluidic devices may contain structural 
supports made from PDMS or glass coverslips. These mechanically stiff structures may alter cell 
behaviors as they begin to migrate into the environment with different stiffnesses (281, 319). Those 
described distinct features, thus, highlight the suitability of the AngioChip to study the 
morphogenetic processes of angiogenesis in vitro. However, similarly to other microfluidic devices, 
the Angiochip also exhibits limitations. For example, retrieval of cells for subsequent biochemical 
assays is possible but not straightforward when a large number of cells are required. In addition, 
the current design of the AngioChip does not enable study of various levels of shear stress as shear 
stress is dictated by a limited number of settings of the platform rocker. Additional modifications are 
thus required to incorporate microfluidic pump to enable studies of different shear stress levels. 
Besides, the field of angiogenesis, we also observe a rapid adaptation of cell culture from 
2D to 3D and to microfluidic platforms in different biological systems. Traditional 2D culture has 
been utilized to expand, culture and, study cellular signaling pathways. Despite their valuable 
contribution in biomedical research, they often fail to recapitulate in vivo tissue functions of many 
cell types or accurately predict drug activities (323). 3D models such as organoids, cell-embedded 
into matrices have provided an additional complexity of tissue organizations to better model disease 
states and drug responsiveness (324-327). Nonetheless, the 3D models also have limitations such 
as incapability to introduce fluid flow and tissue-tissue interfaces, which are crucial for many organs. 
As a results, microfluidic platforms offer the possibility of overcoming these limitations. In recent 
years, we have especially experienced a plethora of more complicated microfluidic-based culture 
platforms that model better disease states and functions of organs. For example, a simplified kidney 
model in a PDMS microfluidic device under physiologically relevant levels of shear forces greatly 
enhanced tissue polarization and induced formation of differentiated and polarized kidney 
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epithelium (328). A living model of human alveolar-capillary interface was created by 
microfabricating a flexible PDMS device. Human alveolar epithelial cells were cultured on one side 
of the porous membrane and exposed to air while human lung capillary endothelial cells were 
culture on the opposite side of the same membrane and exposed to flowing medium. Stretching of 
the flexible PDMS gaskets apply mechanical forces on both the human alveolar epithelial cells and 
endothelial cells to mimic better in vivo functions of lung (329). Moreover, a human blood-brain-
barrier on a chip was developed by lining a porous, fibronectin-coated polycarbonate membrane 
with human brain microvascular endothelium on one side and human astrocytes on the other side 
(330). This device also included embedded microelectrodes to measure trans-epithelial electrical 
resistance across the barrier and demonstrated approximately 25% barrier of living brain, which is 
superior to standard 2D cultures. Our biomimetic model of angiogenesis also demonstrated its 
capability to capture in vivo-like features of sprouting angiogenesis such as digestion of basement 
membrane at initial invasion, formation of tip-stalk cells in multicellular sprout structures, lumen 
formation within sprouts, formation of perfusable neovessels. It can also serve as a screening 
platform to identify the effects of angiogenic factors and the efficacy of angiogenic inhibitors in 
different contexts (281) . Taken together, the microfluidic culture systems including our AngioChip 
provide strong evidence that microfluidic culture systems are capable of reproducing human organ 
physiology. With separate compartmental designs and introduction of fluid flow and mechanical 
cues, they also provide flexibility to dissect the biomolecular and mechanical contributors to tissue 
and organ function, as well as disease development (331). 
 In this thesis, I described the fabrication of a microfluidic platform, the AngioChip, to study 
angiogenic morphogenesis and also examined the role of Cdc42 in branching morphogenesis of 
angiogenesis using the AngioChip. In the study of Cdc42, I showed that inhibition of Cdc42 
disrupted formation of multicellular structures. However, a detailed mechanism of how Cdc42 
regulates collective cell migration in angiogenesis has not been described. Because angiogenesis 
is a dynamic process that involves different cytoskeletal regulators, further studies can focus on 
the effects of different cytoskeletal regulators such as Rac, RhoA, and their GEFs and GAPs to 
100 
 
coordinate the dynamics of cellular organization in sprouts. Rho GTPases exhibited spatial and 
temporal activity during cell migration in 2D. However, how Rho GTPases activity is distributed in 
3D angiogenic sprouts remains to be explored. Molecular constructs that enable spatial and 
temporal activation of Rho GTPases have been described in literature (332). These molecular 
constructs may be employed in the AngioChip platform to explore the spatial and temporal 
regulation of Rho GTPases in angiogenesis.  
Moreover, the physical forces that are generated by tip and stalk cells during sprouting 
angiogenesis can be realized in AngioChip with high resolution imaging and sophisticated algorithm 
of tracking forces. Notch and DLL signaling has been linked to formation of tip and stalk cell (50). 
Since tip and stalk cells undergo dynamic shuffling during sprout formation, a hypothesis that Notch 
and DLL may regulate cytoskeletal proteins or vice versa during shuffling is possible. Endothelial 
cells with knock down or over activation of Notch and DLL can be seeded into the AngioChip to 
elucidate their contributions to cytoskeletal rearrangement during sprouting. Angiogenesis is not 
only regulated by soluble biochemical cues in the environment, it is also regulated by the 
mechanical cues such as substrate stiffness, topography of the extracellular matrix proteins (32, 
333). Thus, incorporating mechanically tunable synthetic materials in the AngioChip will enable 
such studies. Stromal cells in the interstitial tissue also participate in regulating angiogenesis. For 
example, macrophages have been described to enable fusion between vascular tip cells during 
zebrafish development (334). Addition of other cell types such as immune cells, pericytes, 
fibroblasts into the interstitial matrix of the AngioChip will permit studies of cell-cell interactions 
during angiogenesis. 
In this thesis, I also described a development of a pancreatic cancer on a chip by 
introducing a biomimetic pancreatic ductal cancer channel in parallel to the biomimetic blood 
vessel. This study unveils a surprising phenomenon where tumor cells can replace endothelial cells 
from the blood vessels. I also dissected the molecular mechanism that enable endothelial cell 
replacement in PDAC. However, additional experiments are required to further dissect the 
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molecular mechanisms. For instance, we have shown that Alk7 KO PDAC cells are less 
proliferative while ALK5 KO HUVECs are less apoptotic. A heterotypic patterning coculture for 
these two cells are necessary to confirm the effects of Alk7 on PDAC cells and ALK5 on endothelial 
cells to prevent vascular replacement. Additionally, we propose to perform in vivo experiments to 
identify the effect of SB431542 on vascular replacement. Similarly, we also propose to implanted 
Alk7 KO cells into athymic mice to confirm their vascular replacement potential in vivo. It is also 
essential to perform histological section or whole mount confocal imaging of tumor samples to 
identify vessels that are replaced by PDAC in a xenograft model. 
This study on vascular replacement also raises additional questions that need to be 
addressed in future studies. For example, we observed that in the presence of endothelial cells in 
the blood vessels, PDAC appeared to migrate more quickly towards the blood vessels in response 
of the gradient of FBS. This suggests that endothelial cells may secret angiocrine factors to 
modulate migration of PDAC. What angiocrine factors that are involved in this process remain to 
be explored. Interestingly, we consistently observed collective migration of primary PDAC cell line 
PD7591. These collective structures contain a tip-like cell at the front and following stalk cells at 
the rear. Since PD7591 is derived from mice with heterozygous knockout of p53 protein, which 
regulates genomic stability, it is important to verify the collective migration capability of different 
clones of primary PDAC cell lines besides PD7591. One can also ask the question whether tip-
stalk formation in PDAC collective migration is also regulated by Notch and DLL signaling as in 
endothelial cells. Will tip and stalk cells shuffle in PDAC collective migration?  
Our study on vascular invasion specifically focused on the de-endothelialization process 
where PDAC cells have already undergone multiple steps to break into the blood vessels. Thus, 
we have largely neglected the preceding steps of vascular invasion before the de-endothelialization 
process. In particular, since endothelial cells have been shown to deposit a layer of basement 
membrane proteins surrounding the endothelium (281), it is unclear how PDAC cells are able to 
interact with the basement membrane proteins (e.g.: what integrins or MMPs are required to 
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engage tumor cells to the basement membrane and enable disruption of this barrier to allow tumor 
cells to gain access into the interior of the blood vessels). Will inhibiting TGFβ signaling with 
SB431542 block the entry of tumor cells into the blood vessels or the migration of tumor cells in 3D 
interstitial matrix? Additional questions in cellular polarity during invasion of the pancreatic cancer 
cells may also be explored with the PDAC-on-a-chip. For instance, what disturbed cellular polarity 
signaling enables tumor cells to form multiple layer of cells in the biomimetic ductal channel and 
whether invasion into the interstitial matrix occurs before or after formation of multilayer of cells. 
Interestingly, as the cancer cell transition from a surface of ducts into 3D tissue or from 3D tissue 
onto a curved surface of vasculature, they need to switch from a defined basal-apical polarization 
on 2D curved surfaces into a non-defined basal-apical polarization in 3D migration. Understanding 
the molecular mechanisms that regulate this polarization switch may provide strategies to block 
tumor cell migration. 
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